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In melanoma patient specimens and cell lines, the over expression of galectin-3 is associated 
with disease progression and metastatic potential.  Herein, we have sought out to determine 
whether galectin-3 affects the malignant melanoma phenotype by regulating downstream target 
genes.  To that end, galectin-3 was stably silenced by utilizing the lentivirus-incorporated small 
hairpin RNA in two metastatic melanoma cell lines, WM2664 and A375SM, and subjected to 
gene expression microarray analysis.  We identified and validated the lysophospholipase D 
enzyme, autotaxin, a promoter of migration, invasion, and tumorigenesis, to be down regulated 
after silencing galectin-3.  Silencing galectin-3 significantly reduced the promoter activity of 
autotaxin.  Interestingly, we also found the transcription factor NFAT1 to have reduced protein 
expression after silencing galectin-3.  Electrophoretic mobility shift assays from previous 
reports have shown that NFAT1 binds to the autotaxin promoter in two locations.  ChIP 
analysis was performed, and we observed a complete loss of bound NFAT1 to the autotaxin 
promoter after silencing galectin-3 in melanoma cells.  Mutation of the NFAT1 binding sites at 
either location reduces autotaxin promoter activity.  Silencing NFAT1 reduces autotaxin 
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expression while over expressing NFAT1 in NFAT1 negative SB-2 melanoma cells induces 
autotaxin expression.  These data suggest that galectin-3 silencing reduces autotaxin 
transcription by reducing the amount of NFAT1 protein expression.  Rescue of galectin-3 
rescues both NFAT1 and autotaxin.  We also show that the re-expression of autotaxin in 
galectin-3 shRNA melanoma cells rescues the angiogenic phenotype in vivo.  Furthermore, we 
identify NFAT1 as a potent inducer of tumor growth and experimental lung metastasis.  Our 
data elucidate a previously unidentified mechanism by which galectin-3 regulates autotaxin and 
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CHAPTER 1:   
 
 Introduction and Background 
Melanoma Incidence 
 Melanoma is the deadliest form of skin cancer.  In 2012 alone, it is estimated that 
another 76,250 individuals will acquire melanoma and 9,180 deaths will occur [1].  Cutaneous 
melanoma comprises for 5% of all new male cancer patients, and the fifth most prevalent 
following prostate, lung, colon, and urothelial cancer respectively.  The incidence in women for 
2012 is lower and comprises 4% of all cancer patients with only breast, lung, colon, uterine, 
and thyroid cancer being more prominent [1].  Cutaneous melanoma affects all races and 
ethnicities; however, in the U.S., Non-Hispanic whites are most likely to acquire the disease 
over their lifetime, followed by Hispanics, Native Americans, Asians, and African Americans.  
Interestingly, males have a higher incidence rate compared to females in all ethnicities [2].  
 
Clinical Staging and Survival 
In the clinic, melanoma is classified into four distinct stages.  The current staging system is 
based upon a few criteria; tumor thickness, number of lymph node metastasis involved, and the 
presence of distant metastasis [3].  Primary tumors with no identifiable metastasis are 
categorized in the first two stages; stage I and II.  Patients with stage I melanoma are presented 
with primary tumors with a thickness of less than 2 mm.  Stage I patients are further sub 
classified into IA and IB.  IA tumors are less than 1 mm thick with no ulceration and have less 
than 1 mitotic cell per mm2.  Although IB tumors are also classified as less than 1mm thick, 
these tumors are either ulcerated or have greater than 1 mitotic cell per mm2.   Stage IB 
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includes T2a melanoma which is a tumor with a Breslow thickness of up to 2 mm; however, no 
ulceration is present.  In these tumors, the mitotic rate has become a reliable predictor for 
patient survival with lower mitotic rates having a better prognosis [4].  Stage II melanoma 
patients are sub classified into IIA, IIB, and IIC.  These sub-stages are classified based on the 
thickness of tumors ranging from 1mm to greater than 4mm, and whether ulceration is present 
(Table 1) [3].  The survival rate of patients with primary melanomas varies greatly.  Stage IA 
and IB patients have a 10 year survival rate of greater than 80%.  However, Stage II melanoma 
patients have a 10 year survival rate of approximately 40%-70% with the poorest prognosis 
being associated with ulcerated primary tumors that are greater than 4 mm thick [3].  Although 
tumor thickness could be seen as the likely cause for such variation in survival, the mitotic rate 
and the presence of ulceration are also important in predicting the outcome of patients and are 
both independent predictors of survival [3, 5].  In 't Hout et al. has reported that the Melanoma-
specific 10 year survival rate of patients with or without ulceration is 62% and 81% 
respectively.  Patients with ulcerations that are greater than 5 mm in diameter have a 33% 
chance of survival at 10 years as compared to 69% in ulcerated tumors less than 5mm wide.  
Interestingly, in their study, the mitotic rate was significantly associated with the presence of 
ulceration [5].  Stage III melanoma classifies patients with regional lymph node or in transit/ 
satellite metastasis.  These patients are further subgrouped into stage IIIA, IIIB, and IIIC.  The 
criteria for classification include the number of regional lymph nodes involved, the size of the 
lesion within the node (micro- vs. macrometastasis), and whether in transit metastasis is 
observed (Table 1).  As expected, patients that have macrometastasis or multiple lymph nodes 
involved have a poorer 10 year survival rate of approximately 25-35% as compared to patients 
with one or two lymph nodes involved with micrometastasis (approximately 45-65%) [4].  
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Patients with Stage IV disease are presented with distant metastasis to organs such as the lung, 
liver, and brain.  These patients have the worst prognosis with a 10 year survival rate of less 
than 20% [4]. 
 
Melanoma Development    
Melanoma is thought to develop in a stepwise manner.  The initial event during this process is 
the proliferation of normal melanocytes.  These benign nevi present slightly raised lesions in 
the skin with uniform coloration and histology specimens show an increase in the number of 
melanocytes laying near the basement membrane [6].  Next, aberrant uncontrolled growth of 
the benign nevus occurs to develop a dysplastic nevus with random atypia.  Random atypia is 
generally classified as sporadic cells with enlarged and abnormal nuclei.  Clinically these 
lesions can appear asymmetric with multiple colors [6].  The cells then acquire the ability to 
divide and spread throughout the epidermis called the radial-growth phase (RGP).  The cells 
now show continuous atypia throughout the lesion, and clinically can sometimes be observed as 
raised lesions.  Although a few cells can penetrate into the dermis, they fail to form colonies in 
soft agar in vitro [6].  However, as the tumor progresses, more cells invade into the dermis, 
proliferate, and form a lesion beyond the basement membrane border of the epidermis.  This is 
termed the vertical-growth phase (VGP).  These cells can grow in soft agar and are tumorigenic 
when implanted in nude mice [6].  The final step of the primary tumor is for melanoma cells to 
enter the lymphatic system and drain to local (sentinel) lymph nodes or intravasate into the 





A.                                                     B. 
 
  
Table 1.  Tumor Staging and Classification 
(A)  The melanoma TNM categories are tumor thickness (T), lymph node involvement and size 
of metastasis (N), and location of metastasis (M).  (B) Stages I-IV are classified based on the 









Genetic Alterations during Melanoma Progression 
 Throughout melanoma progression, multiple genetic and epigenetic events occur that 
allow for the development of cutaneous melanoma and ultimately metastasis.  For example, the 
genetic alterations in genes such as BRAF, NRAS, PTEN, CDKN2A, and cyclin D1 have 
integral roles in the transition of benign nevi to premalignant lesions (Figure 1).  BRAF is a 
member of the RAF family and acts on the map kinase (MAPK), RAS-RAF-MEK-ERK, 
pathway [7].  The V600E activating mutation within the kinase activation domain of BRAF 
occurs in approximately 40-60% of melanoma patients [8, 9].   This is the most prevalent 
mutation in melanoma and indicates an important role for the MAPK pathway in melanoma 
progression.  Not surprisingly, NRAS, the upstream molecule which activates BRAF, is also 
mutated in melanoma patients.  However, it is only mutated in approximately 20%-30% of 
melanoma patients [10, 11].  These two mutations are mutually exclusive from each other, and 
approximately 20-40% of patients do not have either BRAF or NRAS mutations.  Although the 
MAPK pathway seems essential for melanoma development, reports have shown that mutations 
in BRAF occur in 80% of melanocytic nevi, yet, all of these nevi do not progress into primary 
melanomas [12].  It has also been reported that the introduction of BRAFv600E in melanocytes 
can induce cell senescence and apoptosis [13].  This is counterintuitive to the data that 
overwhelmingly implies BRAFV600E is critical for melanoma progression.  This can be 
explained by acknowledging that other molecules cooperate with BRAF to release cells from 
senescence and continue with uncontrolled growth.  Indeed, the tumor suppressor gene cyclin 
dependent kinase inhibitor 2A (CDKN2A) has been found to inhibit BRAFV600E induced 
growth.  Through alternative mRNA splicing, this gene encodes both p16Ink4A, an inhibitor of 
the cyclin D/CDK4 complex, and the alternate open reading frame p14ARF, an inhibitor of the 
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p53 regulator MDM2 [7, 14, 15].  The levels of p16Ink4A expression in melanocytic nevi is 
greatly increased as compared to normal skin, therefore potentially responding to and 
restricting the proliferative effects of BRAFv600E [16].  Mutations in the p16Ink4A gene have 
been reported in 7% of primary melanomas and 14% of metastatic lesions [17].  The CDKN2A 
gene is more frequently associated with mutations in patients with family history of melanoma, 
and sun exposure.  Other genetic events involved in melanoma progression greatly influence 
their likelihood of developing the disease [18, 19].  These other genetic events could include 
BRAF and NRAS activating mutations.  Without p16Ink4A acting as a "brake" in these patients 
to induce senescence, melanocytic nevi could potentially respond to MAPK activation and 
progress to melanoma.  One report indicates that this is true in the clinic as promoter 
methylation of p16 correlated significantly with NRAS mutations [20].  However, another 
clinical study suggests that there is no correlation between CDNK2A gene deletion and 
BRAF/NRAS mutations [21].  Yet, the latter study did not indicate the presence of methylation 
or gene expression of CDNK2A in patients that did not have genetic deletion.  Nonetheless, the 
release of MAPK induced senescence is most likely attributed to other genes as well as 
CDKN2A.   
 The development of melanoma has also been associated with the loss of PTEN.  PTEN 
acts as a phosphatase to remove phosphates from lipids such as phosphatidylinositol phosphate 
(PIP3) which acts as an intracellular signal induced by growth factors or other extracellular 
stimuli [6, 22].   PIP3 then recruits phosphoinositide-dependent kinase 1 (PDK1), which then 
phosphorylates the survival factor AKT [23].   PIP3 (PtdIns(3,4,5)) is converted back to PIP2 
(PtdIns(4,5)) by  PTEN, thus inactivating the AKT signaling cascade [22]. Initial studies 
identified that chromosomal deletion on 10q occurred in 30-50% of melanomas [24, 25].  Later 
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it was discovered that the tumor suppressor PTEN (hence its name; phosphatase and tensin 
homolog deleted from chromosome ten) was located within this region [26].  Further studies 
demonstrated that mutation/deletion rates of PTEN occur in 30-40% and 10% of cell lines and 
primary melanomas respectively [27, 28].  By using immunohistochemistry, it was observed 
that 90% of the melanomas with no PTEN expression had no mutation or deletion, indicating 
its loss of expression is also attributed to epigenetic regulation and transcriptional repression 
[29].  The effect of PTEN loss in melanoma contributes to cell survival and proliferation 
primarily through AKT activation.  Three isoforms of AKT exist with >80% amino acid 
homology; AKT1, AKT2, AKT3 [30].  Phosphorylation of AKT is increased in the transition 
from dysplastic nevi to primary melanomas [30].  This phosphorylation affects multiple 
processes.  The up-regulation of N-cadherin and its intracellular interaction with AKT can lead 
to the inactivation of the pro-apoptotic molecule BAD, thus promoting survival of melanoma 
cells [31].   
The up regulation of NFκB is associated with AKT activation in melanoma. AKT 
phosphorylates and activates IKKβ which in turn phosphorylates the inhibitor of NFκB, IκB, to 
allow for NFκB transcriptional activation and subsequent transcription of pro-tumorigenic and 
angiogenic genes such as IL-8, VEGF, Cox-2, Bcl-2, and MMPs [32-34].  IκBα-transfected 
melanoma cells decreased tumor size and experimental lung metastasis [35].  The 
microvascular density was reduced in these tumors as well as the expression of both IL-8 and 
VEGF [35].   
 During the transition from the RGP to the VGP, the acquisition of the metastatic 
melanoma phenotype correlates with the loss of the transcription factor activator protein 2 
alpha (AP-2α).  In less metastatic melanoma cells, AP-2α is highly expressed, while its 
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expression is significantly reduced, if not completely lost, in metastatic melanoma cells [36].  
The expression of a dominant negative AP-2α in low-metastatic SB-2 cells increased tumor 
growth and MMP-2 expression in vivo and enhanced their migratory phenotype in vitro [37].   
Its expression is inversely correlated with that of pro-tumorigenic genes such as the membrane 
adhesion molecule MCAM/MUC18 and the protease activated G-protein-coupled receptor 
PAR-1 [36, 38].  Indeed, AP-2α binds to the promoters of both genes and suppresses their 
transcriptional activity [36, 38].  However, as melanoma progresses and the loss of AP-2α 
occurs, the expression of MCAM/MUC18 and PAR-1 expression increases.  The cell adhesion 
molecule MCAM/MUC18 is an important mediator of melanoma progression and silencing 
MCAM/MUC18 expression by lentiviral shRNA has shown a significant reduction in 
melanoma cell migration, invasion, MMP-2 expression, and tumor growth and metastasis [39].  
PAR-1 is an important inflammatory molecule that promotes normal platelet aggregation 
through its cleavage on the extracellular domain by thrombin which acts as a “tethered ligand".  
In melanoma, PAR-1 signaling is important for tumor growth and metastasis by enhancing 
vascular endothelial growth factor (VEGF) and MMP-2 expression within the tumor 
microenvironment, and increasing the expression of another pro-tumorigenic gene, Connexin-
43, while suppressing the tumor suppressor gene Maspin [40-42].   
 Another transcription factor that plays a crucial role during the transition from RGP to 
VGP is the transcription factor c-AMP response element-binding protein CREB (Figure 1).  
Although studies in our lab have shown that CREB protein expression does not change 
significantly in non-metastatic vs. metastatic cells, its phosphorylation and activation is 
increased in metastatic melanoma [43].  This could be due to multiple factors.  One of these 
factors is the ability to respond to signals within the tumor microenvironment.  CREB in the 
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highly metastatic A375SM cell line is phosphorylated in the presence of the platelet activating 
factor receptor (PAFR) ligand platelet activating factor (PAF) [44], while PAF did not increase 
CREB phosphorylation in low metastatic SB-2 cells [45].  PAFR levels were similar in both 
cell lines, suggesting that intermediate signaling proteins are absent in less metastatic cells 
which results in reduced CREB activity.  Once activated, CREB induces the expression of 
multiple pro-tumorigenic genes including MUC18 and MMP-2 [46].  CREB also inhibits the 
expression of genes during melanoma progression.  One of these genes is CYR61.  Silencing 
CREB results in increased expression of CYR61 and reduced motility and invasion in vitro and 
tumor growth in metastasis in vivo.  The over expression of CYR61 resulted in reduced 
invasion in vitro, and decreased tumor growth and metastasis in vivo [43].  CREB can act as a 
survival factor in melanoma as cell.  Over expressing a dominant negative form of CREB 
increased melanoma cell susceptibility to apoptosis [47].  We have also shown that silencing 
CREB increases the cell cycle inhibitor p21waf1.  Increased CREB activity during melanoma 
progression directly suppresses AP-2α expression.  AP-2α is a known positive regulator of 
p21waf1.  Therefore, CREB has a profound effect on melanoma cells by regulating other 
transcription factors that regulate multiple genes involved in melanoma progression [48].  
 Another member of the CREB family, activating transcription factor-2 (ATF-2), has 
been implicated in melanoma [49, 50].  Once activated, ATF-2 leads to the deregulation of c-
Jun, cyclin A, and TGFβ to induce cell growth and melanoma progression [51-54].  Inhibiting 
ATF-2 can significantly reduce the tumorigenic and metastatic potential of melanoma cells 
[50].   
The deregulation of the transcription factors SNAIL and SLUG also promote melanoma 
progression.  These transcription factors are known to negatively regulate E-cadherin, a 
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molecule lost during melanoma progression, and their over expression in melanoma cell lines 
results in reduced levels of E-cadherin [55].  By using siRNA to target SLUG, it was 
demonstrated that the expression of SLUG is required for melanoma cell invasion [46].  
Silencing SLUG also increases melanoma cell susceptibility to chemotherapeutic drugs such as 










Figure 1.  Molecular and Genetic Changes during Melanoma Progression 
The progression of melanoma is a stepwise process. From benign nevus to dysplastic nevus 
genetic mutations occur within the BRAF or NRAS genes.  The loss of PTEN or p16INK4A/ARF 
expression are early events in a subset of melanomas.  The tumor then grows radially 
throughout the epidermis termed the radial growth phase.  The acquisition of multiple factors 
such as CREB and NFκB activation as well as enhanced expression of MCAM/MUC18, PAR1, 
Il-8, MMP-2 and galectin-3 induce the degradation of the basement membrane and invasion of 
melanoma cells termed the vertical growth phase (VGP).  Finally, a few select melanoma cells 
intravasate, circulate, and survive in distant organ sites where metastasis forms.  Reproduced 
with permission from Miller AJ and Mihm MC Jr., N Engl J Med 2006, Copyright 









Status of Current Treatment Modalities for Metastatic Melanoma 
 The first approved drug for the treatment of malignant melanoma was the DNA 
damaging compound dacarbazine (DTIC) in 1975 [57].  DTIC or its oral analogue 
temozolamide remains the standard of care for malignant melanoma.  However, the response 
rate is low at approximately 5-12%.  Long term response occurs in less than 2% of patients 
[58].  High dose IL-2 therapy is another Food and Drug Administration (FDA) approved option 
for patients with inoperable disease.  Unfortunately, only a 16% response rate is observed; 
however, 6% of the patients have a complete response [59].  The treatment of patients after all 
melanoma is surgically removed, termed adjuvant therapy, with stage II and III disease is 
another technique used to reduce the likelihood of disease progression.  After primary tumor 
resection, thick tumors (>4mm) with no sentinel lymph node involvement (Stage II patients) 
may receive adjuvant therapy such as high dose interferon-α [59].  This therapy may include 
unwanted side effects.  Therefore, the risk of metastasis, potential benefits, and side effects 
must be included in the decision process.  If regional lymph node involvement is found, stage 
III patients undergo lymphadenectomy followed by consideration of adjuvant therapy. 
Recently,  clinical trials focusing on intratumoral T-cells and boosting their antitumor 
activity by targeting the T-lymphocyte associated antigen 4 (CTLA-4) with the blocking 
antibody, ipilimumab, have shown promise.  CTLA-4 expression on T-cells acts as a “break” 
by recognizing self and inhibiting the autoimmune response.  Blocking CTLA-4 results in a 
more robust T-cell reaction towards melanoma cells [60]. A phase III clinical trial conducted 
with previously untreated stage IIIC and IV melanoma patients with ipilimumab plus DTIC 
increased two year survival rate to 28.5% as compared to 17.9% with DTIC alone [61].  These 
results have led to the FDA approval of ipilimumab for the treatment of advanced melanoma 
 13 
[62]. Inhibiting another T-cell checkpoint molecule, PD-1, has shown promise in a phase I 
clinical trial that included melanoma, non-small-cell lung cancer, prostate, or colorectal cancer 
[63]. Treatment with the anti-PD-1 antibody BMS-936558 generated an objective response rate 
of 28% (26 of 94 patients).  Of these 26 patients, 13 have had a sustained response for over 1 
year [63]. Interestingly, the phase 1 study also showed that melanomas that do not express the 
PD-1 ligand on tumors, PD-L1, have no response to anti-PD-1.  Only patients with the 
disruption of the PD-L1 ligand on tumors cells with PD-1 on T-cells had a response to therapy 
[63].  A small subset of patients qualify for this treatment regimen (PD-L1 expressing tumors), 
and according to the trial, only a small percentage of those patients have an objective response.  
Although modulation of the T-cells are showing modest responses, they are still a step in the 
right direction in regards to the immunotherapeutic potential for malignant melanoma 
treatment.   
 Recently, with the identification of mutated and activated genes in melanoma 
progression, compounds targeting specific molecules have found their way into clinical trials.  
Among the compounds garnering the greatest attention are those that target the mutant 
BRAFV600E mutation.  In 2011 the FDA approved the first BRAF inhibitor, vemurafenib (PLX-
4032), for the treatment of advanced metastatic melanoma [64].  In 2011, a study was 
conducted on unresectable stage III and distant metastatic stage IV patients.  The response rate 
was 48% and a median progression free survival of 5.3 months as compared to 1.6 months with 
DTIC alone [65].  In a more recent study of patients with stage IV disease, vemurafenib had an 
overall response rate of 53%, progression free survival of 6.8 months, and the overall survival 
rate at 16 months was 50% [66].   
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Brain metastasis has been considered a terminal prognosis for melanoma patients with 
few treatment options.  An intact blood-brain barrier would complicate the transfer of drugs 
into the metastatic lesion.  Fortunately, for the treatment of melanoma brain metastasis, tumors 
tend to create a “leaky” vasculature.  Indeed, using another BRAF inhibitor, dabrafenib, in a 
phase II trial, 20% of melanoma patients had an intracranial response with a duration of 20 and 
28 weeks in previously untreated or previously treated brain metastasis patients respectively.  
Median overall survival of patients with brain metastasis was still rather low at 33 weeks [67].  
Nonetheless, targeted therapy for brain metastasis is a promising method of treatment.   
 Resistance to BRAF inhibitors is almost certain.  Usually this is due to the up-
regulation of the MAPK pathway by alternative means, such as c-RAF, increased activity of 
RAS, increased expression of receptor tyrosine kinases (RTKs) like insulin like growth factor 
receptor (IGFR), or the increased activation of the pro-survival PI3K/AKT pathway [68, 69].  
Furthermore, 50% of melanoma patients do not harbor the BRAF mutation, and these patients 
must not be ignored in regards to targeted therapy.  BRAF resistance and non BRAF mutant 
melanomas have led to the development of MEK and AKT inhibitors.  Although in their 
infancy, phase I trials targeting MEK and AKT are showing promise for the treatment of all 
melanoma patients [70].  Targeting up-regulated molecules in BRAF resistance will 
undoubtedly be the next step in the treatment of melanoma patients.  The investigation of other 
molecules and their role in melanoma progression could also lead to new therapeutic targets.  In 
our case we will focus on galectin-3 and further evaluate its effect on the metastatic melanoma 





Structural Properties of Galectins 
 The evolutionarily conserved galectins share a unique structure termed the carbohydrate 
recognition domain (CRD) [71]  The CRD within the galectin family share characteristic amino 
acid sequences as well as an affinity for β-galactoside sugars (such as lactose), albeit, at a 
relatively weak affinity [72, 73].  Galectins bind to cell surface and extracellular matrix 
proteins at a much higher affinity due to the complex glycans present on proteins [73].  For 
example, galectin-3 preferentially binds to poly-N-acetyllactosamine-containing ([-3Galβ1–
4GlcNAcβ1-]n) glycans which are processed by MGAT enzymes [73].  After the initial transfer 
of Glc3Man9GlcNAc2 by oligosaccharyltransferase in the endoplasmic reticulum, the glyco-
protein is further processed sequentially by MGAT 1, 2, 4 and 5, with removal of mannose 
groups when needed by the mannosidase enzyme ManII.  Finally, in the trans-Golgi, β-
galactosidases remove GlcNAc and add N-acetyllactosamine (Figure 2A) [74].  Galectin-3 
binds well with glycans containing three to four repeating acetyllactosamines [73].  Other 
galectins recognize slightly different glycans. Galectin-1 binds to poly-N-acetyllactosamine as 
well, but requires a terminal β-galactose residue to bind at a high affinity. Although galectins 
have a similar CRD, the overall protein structure can vary.  Therefore, they have been 
subdivided into three unique groups (Figure 2B).  The prototypical galectins contain a single 
CRD and can form homodimers with itself.  These galectins include galectin-1, 2, 7, 10, 13, 
and 14.  Tandem-repeat galectins have two CRDs within the same protein.  The CRDs are 
connected by a small peptide domain that can range from 5 to 50 amino acids in length.  
Galectin-4, 8, 9, and 12 are all members of the tandem-repeat galectins [73].  Interestingly, the 
two CRDs on the same protein can have different binding properties.  In the case of galectin-8, 
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the amino-terminal CRD binds to sialylated glycans while the c-terminal CRD has no binding 
affinity to sialylated glycans [73].   The third group of galectins, the chimeric galectins, is 
unique in that it currently has only one known family member in vertebrates, galectin-3.  The 
group name implies its protein structure; a molecule with multiple domains that represent 
different structures.  The c-terminal end consists of the CRD domain that is present in all 
galectins; however, unlike other galectins, it also contains a proline rich collagen like domain, 
and at the n-terminal end can be post-translationally modified which alters its functional 
properties [75].    
 
Galectin-1 and Galectin-9 in Cancer 
Although there are currently more than 15 galectin family members, relatively few galectins 
have been extensively studied in cancer.  Those that have been studied have shown a variety of 
effects on tumor development.  Besides galectin-3, galectin-1 might be the most studied 
galectin in cancer.  Galectin-1 has been shown to enhance the progression of cervical, lung, 
ovarian cancer, glioma, and melanoma [76-80].  It can have an effect on tumor growth through 
intracellular mechanisms or by influencing the tumor stroma and microenvironment.  For 
instance, galectin-1 binds to T-cell membrane glycoproteins.  Binding of galectin-1 to the T-
cell surface proteins CD7, CD43, and CD45 is necessary for galectin-1 induced apoptosis of 
activated T cells [81-84].  Silencing galectin-1 in B16F10 murine melanoma cells can 
significantly reduce tumor growth in vivo [85]. However, another group reported that tumor 
growth is not effected by galectin-1 expression in Rag-/- Jak-/- mice (mice that do not have B- or 
T-cells) suggesting that galectin-1 affects tumor growth through immunosuppression in this 
model [86].  Direct interaction with melanoma cells by galectin-1 has also been observed.  This 
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induces melanoma cell aggregation by binding to the 90k/MAC-2BP glycoprotein [87].  Once 
aggregated, the outer layer of cells act as a barrier protecting this embolic unit in circulation 
from mechanical and immunological damage.  These aggregated cells are more likely to 
survive and grow in the distant organ parenchyma [88].  Although galectin-1's primary function 
is carbohydrate binding dependent, intracellular roles have also been established.  The 
interaction of galectn-1 with RAS molecules has been extensively studied by Yoel Kloog and 
others.  For instance, the activated, GTP loaded HRAS briefly binds to galectin-1 at the cellular 
membrane creating nanoclusters of HRAS.  This signal is then propagated to RAF and the 
downstream MAPK pathway [89].  Galectin-1 is essential for membrane localization of HRAS.  
Silencing galectin-1 with shRNA results in a dispersed HRAS throughout the cytoplasm and 
galectin-1 antisense reduced the number of HRAS transformed Rat-1 cells [90].  Although, this 
has significant implications in other cancers, these studies are less important in melanoma.  
NRAS is the RAS family member commonly deregulated during melanoma progression and it 
has been reported that this nanoclustering phenomenon does not occur with NRAS.  
Furthermore, with 50% of melanoma patients harboring an activating mutation in the 
downstream target of NRAS, BRAF, it is less likely that galectin-1 contributes to melanoma 
growth by this manner.  Yet other roles such as cell aggregation, immune suppression, and cell 
survival have been established which could potentially enhance melanoma development and 
chemotherapeutic resistance.  Interestingly, galectin-1 can be found in the nucleus where it 
binds to the spliceosome complex, and enhances splicing of mRNA substrates [91].  However, 
currently, no known specific pre-mRNA targets have been established.  Identifying whether 
galectin-1 enhances the expression of pro-tumorigenic genes through mRNA splicing must be 
further studied in melanoma.  Cell survival and the inhibition of apoptosis has become a critical 
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problem in regards to chemotherapy.  Silencing galectin-1 renders B16F10 cells more sensitive 
to temozolomide treatment in vitro, thus, targeting galectin-1 in melanoma could prove useful 
[92].   
 Not all galectins have a pro-tumorigenic effect.  In melanoma, reduced galectin-9 
expression significantly correlates with lymph node metastasis, and galectin-9 expressing 
primary tumors were less likely to metastasize [93].  Furthermore, the 5 year overall survival 
was significantly better in patients whose primary melanomas expressed high levels of galectin-
9 [93, 94].  In vitro galectin-9 induces aggregation of melanoma cells through its CRD [93].  
However, in vivo, galectin-9 secretion from melanoma cells reduced the number of 
experimental lung metastasis [93].  Intravenous injection of galectin-9 also resulted in fewer 
metastatic lung colonies of B16F10 melanoma cells [95].  In vitro the authors show that 
melanoma cell binding to the cell adhesion molecule commonly located on endothelial cells, 
VCAM-1, is reduced in the presence of exogenous galectin-9.  This phenomenon is 
carbohydrate binding dependent as the melanoma cell binding to VCAM-1 is rescued with the 
addition of lactose [95].     Galectin-9 also inhibited melanoma cell adhesion to collagen I, IV, 
fibronectin, and laminin coated plates [95].  Therefore, galectin-9 might prohibit melanoma cell 
adhesion to endothelial membrane proteins and extracellular proteins rather than "bridge" them 










Figure 2.  Carbohydrate Binding and Structural Properties of Galectin-3 and its Family 
Members  
 
(A) Oligosaccharyltransterase (OT) transfers the glycan to N-X-S/T motifs in the endoplasmic 
reticulum.  The glycol protein is then transported to the Golgi where it is further modified in the 
cis-, medial- and trans- Golgi.  The disassociation constant (Kd) is shown for galectin-3 and the 
processed glycans.  The lower the Kd in µM, the tighter the bond.  (B)  The three different 
types of galectins are shown with the corresponding galectins within each group.  An example 
of each group and their functions are given.  Prototypical galectins have one CRD and dimerize 
together.  Tandem-repeat galectins have two CRD that are linked by short peptide.  Galectin-3 
belongs in the chimeric group in which it contains one CRD, a collagen like domain, and an N-
terminal domain.  Adapted from Lau KS and Dennis JW, Glycobiology 2008 and Braeuer RR 


















Galectin-3 in Cancer  
Cell Adhesion, Invasion, and Angiogenesis 
The glycosylation process by mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase (MGAT) enzymes is critical for galectin-3 binding to β-galactosides.  
Galectin-3 can either homodimerize with itself at the N-terminal domain, or can form a 
pentameric structure when binding to multiple glycans [94]  Silencing MGAT1 in HeLa and 
PC-3 cells significantly reduced their migratory phenotype.  MGAT1 shRNA also resulted in 
significant reduction of PC-3 orthotopic tumor growth and lung metastasis in nude mice [96].  
MGAT5 silencing in PC-3 cells has shown a marked reduction in their invasive phenotype as 
well as reduced tumor growth after orthotopic injection in the prostate glands of mice [97].  
Studies have shown that highly metastatic B16F10 murine melanoma cells have high levels of 
branched N-oligosacharides as compared to less metastatic B16F1 cells [98].  When incubated 
on lung tissue specimens, B16F10 melanoma cells adhered at a much higher affinity as 
compared to B16F1.  The lung specimens also had higher levels of galectin-3, and the authors 
postulate that galectin-3 in the lung parenchyma is important for the attachment of melanoma 
cells to the lung endothelium [98].  This hypothesis is supported with galectin-3 knockout mice 
by which B16F10 lung metastasis is significantly reduced.  They reported that host galectin-3 is 
required for melanoma cell extravasation into the lung and binding of B16F10 melanoma cells 
to tissue sections from Gal-3-/- mice was also less as compared to wild type mice [99].  
Galectin-3 has a profound effect on immunosurveillance of tumor cells.  Exogenous galectin-3 
can induce T-cell apoptosis [100].  CD45 expression on the surface of T-cells increases the 
apoptotic sensitivity [101].  Galectin-3 also binds to and reduces the association of T-cell 
receptors (TCR) with CD4 or CD8 co-receptors.  The inhibition of galectin-3 with modified 
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citrus pectin increased the expression of IFN-γ, IL-2, and tumor necrosis factor (TNF) by tumor 
infiltrating lymphocytes (TILs) (Figure 3) [102].      
 The expression of galectin-3 is not limited to the stromal tissue.  Its expression is also 
found in tumor cells.  High levels of immunohistochemical staining have been correlated with 
the progression of melanoma, glioma, breast, colon, and thyroid cancer [103-106], and its 
expression in melanoma tumors isolated from patients can be found in both the cytoplasm and 
nuclear compartments [103]. Galectin-3 has a prominent role in cancer cell motility.  Silencing 
galectin-3 in B16F10 murine melanoma, and pancreatic cancer cell lines significantly reduces 
their migratory phenotype as analyzed by the in vitro wound healing scratch assay [107, 108].  
The overexpression of galectin-3 in colon cancer DLD-1 cells increased motility, lamellipodia 
formation, and the rate of wound closure as observed by the scratch assay [109].  MAPK 
phosphorylation was increased in a KRAS dependent manner in DLD-1 cells when galectin-3 
is overexpressed.  Silencing KRAS reduced the motility of galectin-3 overexpressed DLD-1 
cells [109].  The link between KRAS mediated motility and galectin-3 is not surprising.  
Galectin-1 has already been shown to nanocluster HRAS and galectin-3 has been reported by 
the same group to bind with KRAS [110].  The CRD of galectin-3 could potentially bind to the 
farnesyl group of KRAS.  Changing this hydrophobic pocket with a V125A substitution 
rendered the over expression of galectin-3 ineffective on KRAS nanoclustering.  More 
interestingly, silencing of galectin-3 reduced the amount GTP loaded KRAS [111].  This could 
be a significant finding for cancers such as thyroid, colon, and pancreatic cancer.  However, 
like galectin-1, galectin-3 has far less of an effect on NRAS nanoclustering [112].  Its effect on 
motility is not only attributed by RAS signaling.  Galectin-3 co-localizes with N-cadherin in 
cancer cells, and this lattice structure is blocked with the addiction of lactose or MGAT5 
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siRNA [113].  Therefore, extracellular galectin-3 contributes to N-cadherin localization at lipid 
rafts and could contribute to N-cadherin turnover and migration [113].   
 The transition from the radial growth phase to the vertical growth phase requires more 
than just a migratory phenotype.  The cells must degrade the basement membrane and the 
extracellular matrix in order to invade through the tissue and extravasate into the vasculature.  
Indeed, galectin-3 has been shown to affect the expression of matrix metalloproteinases, 
proteins involved in breaking down the extracellular matrix.  Silencing galectin-3 in B16F10 
melanoma cells reduces MMP-1 expression and results in decreased invasion through Matrigel 
[107].  Another matrix metalloproteinase, MMP-2, has reduced activity in galectin-3 silenced 
C8161 melanoma cells as observed by the zymography assay [114].  
Interestingly, the collagen like domain of galectin-3 can be cleaved by MMP-2 between 
G32-A33 and A62-Y63 resulting in 27 and 22 kDa peptides.  This has been considered as a 
potential tool for distinguishing between pro- or active MMP-2 in patient specimens by staining 
for cleaved galectin-3 [115].  Moreover, cleavage of galectin-3 by MMP-2 is functionally 
relevant in tumor growth.   Cleavage resistant galectin-3 transfected BT-549 cells resulted in 
reduced tumor growth and angiogenesis in vivo compared to BT-549 with cleavable galectin-3 
[115].  The authors identified that cleaved galectin-3, specifically peptides 1-62 and 33-250, 
acts as a migratory chemoattractant for endothelial cells [116].  Thus, cleavage of galectin-3 
might contribute to angiogenesis.  Others have shown that exogenous galectin-3 can induce 
VEGF expression in an AKT dependent manner and this contributes to tube like formation in 
vitro.  However, they did not analyze whether whole or cleaved galectin-3 is responsible, nor is 
the mechanism by which galectin-3 contributes to AKT activity investigated [117].  It has also 
been suggested that galectin-3 binds to VEGFR2 on endothelial cells to prolong VEGF 
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signaling and enhance angiogenesis [118].  Galectin-3 can also enhance VEGF and bFGF 
mediated tube like formation of HUVEC cells in vitro by binding to integrin αvβ3 in a 
carbohydrate dependent manner.  Blocking integrin αvβ3 or galectins-3 with lactose reduces 
the effect of VEGF and bFGF on angiogenesis [119].  Galectin-3 can also affect tube like 
formation of melanoma cells.  As shown with C8161 cells, silencing galectin-3 results in 
reduced tube like formation on Matrigel coated wells [114]. 
 
Anti-Apoptotic Properties of Galectin-3 
 Targeting cancer cells by cytotoxic drug can be an effective chemotherapeutic approach 
to treating cancer patients.  Unfortunately, the results are temporary or ineffective due to the 
inhibition of cancer cell apoptosis by various molecules.  The intrinsic apoptotic pathway 
results in increased cytochrome-c release from the mitochondria.  Cytochrome-c then binds 
with APAF1 to generate an apoptosome.  Caspase-9 activation occurs and subsequent caspase-
3 cleavage initiates cell death [120, 121].  This cell death pathway can be prevented by the 
inhibition of cytochrome-c release.  The BCL-2 family of proteins are known to act as 
“gatekeepers” to prevent cytochrome-c release from the mitochondria [122].  Galectin-3 shares 
a similar NWGR motif that is located on the BH1 domain of the BCL-2 family [123, 124].  
Phosphorylation of galectin-3 by casein kinase I at Ser6 has a significant effect on its glycan 
binding and apoptotic properties.  Once phosphorylated, galectin-3 binds at a much lower 
affinity to extracellular proteins [125], and increases its anti-apoptotic function [126].  Under 
chemotherapeutic stress, endogenous galectin-3 in breast cancer cells is transported from the 
nucleus to the cytoplasm to inhibit apoptosis, however, Ser6 mutants remained within the 
nucleus and did not promote cell survival [127]. Phosphorylation at Ser6 is required for export 
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from the nucleus and into the cytoplasm where it can act as an anti-apoptotic molecule [128].  
This suggests that post-translational modification of galectin-3 has a profound effect on its 
functional role and cellular localization during cancer progression.  Galectin-3 located at the 
surface can also enhance cell survival by inhibiting TRAIL-induced caspase-8 activation.  
TRAIL resistant cells have higher levels of galectin-3 that co-localize with TRAIL receptors at 
the plasma membrane [129].  In response to TRAIL, the receptors DR4 and DR5 are 
internalized.  In the presence of galectin-3, the receptors remain located on the cell surface with 
the addition of TRAIL and apoptosis is less likely to occur [129].  Whether galectin-3 inhibits 
the initial activation of the death receptors by blocking TRAIL binding or through glycan 
branching of DR4 and DR5 thus preventing internalization remains unknown.  More studies 
must be performed to identify how galectin-3 inhibits TRAIL induced cell death. 
 
The Potential of Treating Cancer by Targeting Galectin-3 
 As galectin-3 acts as a pro-tumorigenic molecule, it seems advantageous to develop 
compounds that selectively target galectin-3 for potential cancer treatment.  Targeting 
extracellular galectin-3 can be achieved by simply sequestering the CRD binding domain with 
polysaccharides rich in galactoside residues.  These polysaccharides include modified citrus 
pectin (MCP) and okra pectin [130].  Modified citrus pectin, a soluble fiber from citrus fruit, is 
a non-toxic pectin that can be given orally [131].  MCP has been shown to reduce B16F10 cell 
aggregation and lung metastasis [130].  Oral delivery of MCP significantly reduced the number 
of spontaneous lung metastasis in a prostate cancer murine model [131].  The direct binding of 
galectin-3 to breast cancer cells is drastically reduced in the presence of MCP.  MCP can also 
directly affect angiogenesis by blocking galectin-3 binding to endothelial cells which was 
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shown to reduce chemotaxic migration of HUVEC cells in vitro [132].  The okra pectin, 
rhamnogalacturonan, has also been shown to bind to galectin-3, and the addition of okra pectin 
in B16F10 cells induced apoptosis [133].  These non-toxic polysaccharides could prove useful 
for stage II patients who have no clinical evidence of metastatic lesions, but would prefer a safe 
adjuvant treatment after resection of the primary tumors with no unwanted side effects.  
However, this hypothesis need to be further evaluated.   
Small peptides have also been found to have an affinity for the galectin-3 CRD [134].  
A more promising therapeutic option is using these peptides as homing devices for galectin-3 
expressing tumors.  Conjugating galectin-3 targeting peptides to “packaged” liposomes 
containing cytotoxic drugs or siRNA could prove useful.  One group has already shown that 
radiolabeled peptides targeting galectin-3 specifically bind to galectin-3 expressing tumors in 
vivo [135].  However, peptide uptake into the liver and kidneys is currently an obstacle that 
must be cleared before these treatment modalities could be considered safe and efficient.  
Targeting galectin-3 with large molecules like pectins and peptides could however limit 
their therapeutic potential.  These molecules do not readily pass through the plasma membrane, 
and therefore, they cannot inhibit intracellular galectin-3 functions.  However, small molecule 
inhibitors could be developed to target both intracellular and extracellular functions of galectin-
3 with one drug.  The amino acid G182A mutation on galectin-3, located in the “NWGR” anti-
death domain of the CRD region has been shown to reduce cell survival as well as the 
carbohydrate binding to Galβ1-3glcNAc located on cell surface molecules [136].  Therefore, 
targeting amino acid G182 and the surrounding structure with a small molecule could 
potentially inhibit cell survival as well as prevent cell adhesion mediated metastasis.   
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Galectin-3 in WNT/β-Catenin Signaling  
 The canonical Wnt signaling pathway begins with a Wnt family ligand binding to the 
frizzled receptor.  The frizzled receptor then recruits dishevelled to the membrane for 
activation.  Once activated, dishevelled blocks GSK3β from phosphorylating β-catenin.  This 
results in stable β-catenin and allows for its translocation from the cytoplasm to the nucleus to 
transcribe target genes [137].  The role that the Wnt/β-catenin pathway plays in malignant 
melanoma is controversial.  This pathway has been reported to promote or antagonize 
melanoma progression depending on the cells, patient samples used, or context of the genes 
involved [138].  Studies have shown that nuclear beta catenin correlates with improved survival 
and benign melanoma express higher levels of β-catenin as compared to metastatic melanomas 
[139-142].  Another report indicates that β-catenin expression in melanocytes inhibited their 
migratory phenotype, but the over expression of β-catenin in melanoma cells increased the 
number of experimental lung metastasis [143].  β-catenin independent Wnt signaling by ligands 
such as WNT5A are associated with melanoma metastasis [144].  Galectin-3 is a binding 
partner of β-catenin and contains a GSK3β phosphorylation consensus sequence of 
S92XXXS96.  Indeed GSK3β phosphorylates galectin-3 [145, 146].  Casein kinase I (CK1) is 
also implicated in the WNT/Beta catenin pathway and CK1 mediated phosphorylation at Ser6 
of galectin-3 occurs.  However, unlike proteasomal degradation of β-catenin, phosphorylation 
of galectin-3 might have different effects such as nuclear localization or biological functions.  
Nevertheless, this implicates galectin-3 within the WNT signaling pathway.  Its role on cancer 
progression has not been fully understood beyond the anti-apoptotic properties and nuclear 
localization resulting from phosphorylation at Ser6 by CK1.     
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Galectin-3 and its Regulation of Downstream Genes     
 Galectin-3 can affect multiple pathways by performing different functions such as 
carbohydrate binding on cell surface proteins, intracellular protein binding, and nuclear 
localization.  These functions can have a profound effect on signaling pathways that affect the 
expression of multiple genes that could enhance tumor progression.  Early research on galectin-
3 identified the cell proliferation gene cyclin D1 as a downstream transcriptional target of 
galectin-3.  Initial studies showed that the over expression of galectin-3 in breast epithelial cells 
enhanced the promoter activity of cyclin D1 [147].  Later, it was found that galectin-3 can bind 
directly with β-catenin and colocalize together within the nucleus.  This resulted in up 
regulation of cyclin D1 and c-Myc in the breast BT549 epithelial cell line [145].  Interestingly, 
another group overexpressed galectin-3 in BT549 cells and observed the same increased 
expression of cyclin D1.  Furthermore, by gene expression array, they identified a large group 
of genes that are deregulated when galectin-3 is over expressed and confirmed the up regulation 
of cyclin D1, insulin-like growth factor binding protein 5, protease serine 3, and dual 
specificity phosphatase 6 by western blot [148].  The over expression of galectins-3 with a Ser6 
mutation to Glu did not have the same effects, showing the important nature of phosphorylation 
at Ser6 to induce the expression of select genes [148].  Moreover, injection of BT549 cells with 
the galectin-3 expression vector in nude mice generated tumors while the empty vector and 
Ser6 galectin-3 mutant remained tumor free for greater than 40 days [148].  
 Our lab has also reported that galectins-3 can differentially regulate genes that promote 
melanoma progression.  Silencing galectin-3 in A375SM and C8161 results in reduced 
expression of the inflammatory cytokine interleukin-8 (IL-8) and fibronectin-1 [114].  The 
endothelia cell adhesion molecule VE-cadherin is highly expressed in C8161 melanoma cells.  
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Silencing galectin-3 in this cell line resulted in ~70% reduction of VE-cadherin.  The 
transcription factor EGR-1 was found to bind to both the IL-8 and VE-cadherin promoter after 
silencing galectin-3.  Over expressing EGR-1 significantly reduced VE-cadherin and IL-8 
protein expression [114].  Therefore, it is likely that galectins-3 suppresses EGR-1 activity 
during melanoma progression.  Galectin-3 silenced C8161 melanoma cells were injected into 
mice and showed a significant reduction in tumor growth and metastasis.  
Immunohistochemical staining confirmed the down regulation of IL-8, VE-cadherin, and 
MMP-2, and less vasculature was observed by CD31 staining [114].  Although, the expression 
of MMP-2 is significantly reduced in galectin-3 silenced C8161 cells, there was no observed 
change in A375SM cells.  Therefore, galectin-3 regulation of select genes could be cell line 
dependent.  These data clearly indicate that galectin-3 could regulate multiple genes during 
melanoma progression.  Yet, the majority of the genes have yet been identified, and how they 






Figure 3.  The Contribution of Galectin-3 to Melanoma Growth and Metastasis   
Galectin-3 expression can enhance tumor cell binding with endothelial cells and potentially 
enhance melanoma cell extravasation.  Galectin-3 inhibits immunosurveillance by inhibiting T-
cell receptor and either CD4 or CD8 activation.  In CD8 T-cells, this results in reduced IL-2, 
INF-γ, and TNF levels.  Binding of galectin-3 on CD45 in T-cells activates T-cell apoptosis.  
Intracellular galectin-3 can induce the expression of metastatic genes such as IL-8 and VE-








Galectin-3 is highly expressed in primary and metastatic melanoma patient specimens as 
compared to benign nevi [103].  Others have shown that galectin-3 increases the metastatic 
phenotype of B16F10 murine melanoma cells.  We have previously shown that silencing 
galectin-3 can differentially regulate specific genes such as IL-8, VE-cadherin, and fibronectin 
[114].  In breast epithelial cells galectin-3 drastically changed their gene expression profile.  
Therefore, in melanoma, it is likely that novel, previously unidentified genes could be 
deregulated by galectin-3 in malignant melanoma cells.  Our study will identify these novel 
downstream targets, characterize their regulation by galectin-3, and evaluate their role during 
melanoma progression. 
Therefore, we hypothesize that galectin-3 differentially regulates the expression of genes 
that promote the metastatic melanoma phenotype. 
To test this hypothesis we developed the following aims: 
1. Determine the In Vitro Migratory, Invasive, and Colony Formation Potential of 
Melanoma Cell Lines after Silencing Galectin-3 Expression with Lentiviral-Based 
shRNA 
2. Identification of Novel Downstream Target Genes of Galectin-3 that Contribute to 
the Metastatic Melanoma Phenotype 
2.1. Galectin-3 as a Potential Regulator of Autotaxin Expression in Melanoma 
Cells  




CHAPTER 2:  Materials and Methods 
 
Cell Culture  
The A375SM melanoma cell line was established through intravenous injection of A375-P in 
which the pooled lung metastasis were collected and grown [149]. The WM2664 melanoma 
cell line was purchased from the American Type Culture Collection, and are highly metastatic 
in nude mice [150].  The SB-2 melanoma cell line was isolated from a primary cutaneous 
lesion and is non-metastatic and poorly tumorigenic in mice [151].  All cell lines except 
WM902B were cultured in Eagles minimum essential media (MEM) supplemented with 10% 
FBS.  WM902B was culture in RPMI-1640 with 5% FBS.  The human embryonic kidney cells 
(293FT) used for lentiviral shRNA and over expression vectors were maintained in DMEM 
supplemented with 10% FBS.   
 
Lentiviral shRNA and siRNA  
Galectin-3 targeting shRNA 5’-GTACAATCATCGGGTTAAA-3’ and Non Targeting shRNA 
5’-TTCTCCGAACGTGTCACGT-3’ were designed with a hairpin and inserted into a 
pLVTHm lentiviral vector.  The lentivirus was then produced by transfecting 293FT cells with 
the pLVTHm vector containing either the Galectin-3 or NT shRNA sequence, the packaging 
plasmid (MD2G), and the envelop plasmid (PAX2) to produce a viable virus.  The NT shRNA 
has no homology to any known human genes.  The supernatant was collected containing a 
mature virus and was concentrated 10x.  WM2664 and A375SM cells were plated at 70% 
confluence on a six well plate and were transduced with 500ul MEM / 500ul of supernatant 
containing the virus and were incubated overnight.  The cells were then grown and the top 30% 
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GFP expressing cells were cell sorted by FACS.  NFAT1 siRNA was purchased from Sigma 
and transfected into WM2664 and A375SM melanoma cells by using HiPerFect Transfection 
Reagent (QIAGEN) according to the manufacturer’s instruction.  The siRNA sequence from 
Sigma targeting 5’-CTGATGAGCGGATCCTTAA-3’ was used to stably silence NFAT1 by 
inserting it or NT shRNA into a PcDH vector and packaged within the lentiviral system as 
described above.      
 
Nontargetable Galectin-3 Expression Vector   
The Galectin-3 gene was amplified from A375SM cDNA with the following primers; gal-
3AsclF- TTGGCGCGCCAAATGGCAGACAATTTTTCGCTCC and gal-3EcoR1R- 
CGGAATTCCGTTATATCATGGTATATGAAGCAC, cut with AscI and EcoR1 restriction 
enzymes, and inserted into the OG2 puromycin resistant vector.  The Galectin-3 shRNA 
targeting site was mutated to ATATAACCACCGTGTCAA (underlined nucleotide designates 
mutated sites) with the following primers; gal-3mutF-GAATGATGCTCACTTGTTG-
CAATATAACCACCGTGTCAAAAAACTCAATGAAATCAGC and gal-3mutR- GCTG-
ATTTCATTGAGTTTTTTGACACGGTGGTTATATTGCAACAAGTGAGCATCATTC. The 
virus was then produced with the OG2 Empty vector or OG2-Gal-3 Rescue, MD2G, and PAX2 
plasmids as previously described.  WM2664 and A375SM Gal-3 shRNA cell lines were then 
transduced with 800ul MEM / 200ul supernatant containing virus overnight and were selected 





Autotaxin and NFAT1 Expression Lentiviral Vector   
Autotaxin and NFAT1 genes were cloned from A375SM cDNA.  Autotaxin was cloned with 
the following primers; ATXXbaIF-TGCTCTAGAGCCACCATGGCAAGGAGGAGCTC-
GTTCC and ATXBamHIR- CGGGATCCTTAAATCTCGCTCTCATATG.  NFAT1 was 
cloned with the following primers; NFAT1XbaIF-GCTCTAGAGCCACCATGCAGAGA-
GAGGCTGCGTTCAG and NFAT1NotIR-ATAAGAATGCGGCCGCTCATAATATGTTTT-
GTATCCAG. Either gene was cut with the designated restriction enzymes, inserted into a 
PcDH vector and packaged in a lentiviral virus as previously described. 
 
Western Blot Analysis   
To detect Galectin-3 and NFAT1, 20ug of whole cell protein lysate was loaded on SDS-PAGE 
and transferred to PVDF membranes.    To detect Autotaxin protein expression, 1.5 million 
cells were plated in a 10cm dish and were incubated with 8ml of serum free MEM for 48hrs.  
The supernatant from cell culture was concentrated to 100ul, was protein precipitated as 
previously described, and resuspended in 6M urea lysis buffer [43].  A total of 10ug of protein 
from the supernatant was loaded onto SDS-PAGE.  Blots were incubated with primary 
antibodies rabbit polyclonal anti-Galectin-3; anti-NFAT1 Santa Cruz Biotechnology; anti-
Autotaxin Abcam.  To confirm equal loading of the supernatant, the membrane was coomassie 
blue stained and destained with 40% methanol, 50% water, and 10% acetic acid until protein 





Invasion and Migration Assays   
Matrigel invasion assays were performed with Biocoat Matrigel invasion chambers (BD 
Biosciences) as previously described [43].  Boyden chambers were plated and assayed in the 
same manner.  Wells were repeated in triplicate and the invaded/migrated cells were quantified 
per field of view and statistically analyzed.  
 
Soft Agar Colony Formation Assay   
A 0.6% agar in MEM bottom layer is plated in 6 well plates and allowed to solidify.  The cells 
are then suspended in 0.8% agar/MEM and plated at 5x103 cells per well in triplicate.  
Following 30 days incubation, the number of colonies is quantified in triplicate wells. 
 
Semi Quantitative RT-PCR   
Isolation of RNA was performed with the RNAqueous kit (Ambion) and reverse transcribed 
with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  Real time 
PCR was performed with the Autotaxin Taqman Gene Expression Assay and standardized to 
18s (Applied Biosystems).  LPAR1-6 Taqman Gene Expression Assays were acquired from 
Applied Biosystems.  All six receptors were detectable by qRT-PCR and standardized to one 
with the SB-2 melanoma cell line.  Autotaxin and NFAT1 Taqman Gene Expression Assays 
were acquired from Applied Biosystems and qRT-PCR was performed on WM2664 and 





mRNA Stability Assay 
Melanoma cells were subjected to 2, 4, 6, 8, or 12 hours of actinomycin D treatment at 10 ug/ul 
concentration followed by RNA isolation by the RNAqueous kit (Ambion).  cDNA was 
generated and qRT-PCR for autotaxin was performed.   
  
Autotaxin Activity Assay   
To analyze Autotaxin lysophospholipase D activity, the fluorescent compound FS-3 (L-2000; 
Echelon) was used as previously described [152].  Briefly, cells were plated for supernatant 
collection as described previously.  The supernatant was then concentrated to a volume of 
250ul.  A total of 50ul of supernatant from WM2664 and A375SM NT and Gal-3 shRNA cell 
lines were plated in triplicate in a clear bottom white walled plate.  The volume for each well 
was brought up to 100ul with reaction buffer (Final concentrations in the assay: 140 mM NaCl, 
5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 50 mM Tris, pH 8.0), and 5 μM FS-3.  Serum 
Free MEM was used as a control to confirm that there is no lysophosholipase D activity within 
unconditioned media (data not shown).  The plate was then placed in the Spectra Max Gemini 
EM (Molecular Devices) fluorescence reader at 37°C and read every two minutes for six hours 
with an excitation at 485 nm and emissions reading at 538 nm.  A volume of 25 ul supernatant 
and 25 ul 2x loading buffer for each sample were run on SDS-PAGE and silver stained with 
SilverquestTM Silver Staining Kit (LC6070; Invitrogen) to confirm equal total protein 
concentration.        




Chromatin Immunoprecipitation Assay   
ChIP assays were performed with the ChIP-IT Express Enzymatic kit (53009; Active Motive) 
according to the manufacturer’s protocol and as previously described [43].  Fixed protein DNA 
complexes were pulled down with anti-NFAT1 antibody (sc-7296; Santa Cruz Biotechnology), 
were Protein-DNA reverse cross-linked, and prepared for PCR.  PCR was performed 
surrounding both NFAT1 binding sites with the following primers; NFATF- 
GCTCAAACTGCCAGCAAAAT and NFATR- CACAGGGTGTTCACAAATCG.  The PCR 
product was run in a 1.5% agarose gel. 
 
Reporter Constructs and Luciferase Activity Analysis   
The Autotaxin promoter was cloned from A375SM melanoma cells to encompass 930 base 
pairs upstream of the transcriptional initiation site with the following primers; 930KPN1F-
GGGGTACCCCCACAATAGCCTCAAAGG and 50BglIIR-GAAGATCTTCTCTTTGCCTT-
CACGGAG.  PGL-3 basic was cut with kpn1 and bglII restriction enzymes and the Autotaxin 
promoter was inserted.  Direct site mutagenesis of NFAT1 binding sites were carried out using 
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) according to manufacturer’s 
instructions.  Cells were plated in a 24 well plate with 2.0 x 104 cells/ well.  After 48 hours, 
transfection with Lipofectin (Invitrogen) was performed according to manufacturer’s 
instructions.  Briefly, each well was transfected with 0.8 μg of the basic pGL3 expression 
vector with no promoter sequence or with 0.8 μg of pGL3 with the inserted Autotaxin 
promoter, single mutation, or double NFAT1 mutation sites.  As a control, 2.5 ng of 
cytomegalovirus (CMV) driven renilla luciferase construct (pRL-CMV, Promega) was included 
per well. Each group was plated in replicates of six.  After 48 hours the cells were lysed, and 
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luciferase activity was assayed with the Dual Luciferase Reporter Assay System (Promega) 
according to the manufacturer’s instructions.  The ratio of PGL3 firefly to CMV-driven renilla 
luciferase activity was used to normalize each sample.      
 
Nuclear Run-On Assay   
Nuclear run-on was performed as previously described [153].  Briefly, the nuclei fractions of 
A375SM NT shRNA and Galectin-3 shRNA melanoma cells was collected and RNA synthesis 
was performed in vitro with ATP, CTP, GTP, and biotin-16-UTP.  Reaction was stopped after 
30 minutes and 50ul of Dynabeads M-280 (Invitrogen) were added to capture biotin labeled 
RNA.  The beads were then washed with 2x standard saline citrate and resuspended in H2O.  
RNA was synthesized into cDNA with the High Capacity cDNA Reverse Transcription Kit, 
and qRT-PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems).  
Freshly transcribed Autotaxin was amplified in triplicate with ATXF-GTTCACTTTTGCCG-
TTGGAG and ATXR-ACCTTCCTCCCATCCTTCTG and standardized to GAPDH primers; 
GapdhF- AAGGTCATCCCTGAGCTGAA and GapdhR- AGGTCCACCACTGACACGTT.  
The Rq Max is shown.  
 
Immunoprecipitation of FLAG-tagged NFAT1 
NFAT1 was inserted into the pFLAG CMV 5.1 plasmid. WM2664 and A375SM melanoma 
cells with either NT shRNA or galectin-3 shRNA were plated into a 10cm dish.  After 24 hrs, 
the pFLAG-NFAT1 CMV5.1 plasmid was transfected with FuGENE 6 (Roche).  The 
proteasome inhibitor Bortezomib at 20 nM was added to the media.  Following 24hrs, the cells 
were lysed and FLAG immunoprecipitated with the FLAG Immunoprecipitation Kit (Sigma) 
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according to the manufacturer’s instructions.  Western blot analysis of NFAT1 with anti-
NFAT1 was then performed.  Parental cells were used as a negative control for 
immunoprecipitation of FLAG.   
 
Immunohistochemistry and Immunofluorescence   
Mice were sacrificed and tumors were removed.  Half of each tumor was formalin fixed and 
paraffin embedded while the other half was placed in optimum cutting temperature and frozen 
at -80°C.  Mouse anti-Galectin-3 antibody (Santa Cruz Biotechnology) was used in 
combination with citrus buffer antigen retrieval and mouse anti-Autotaxin (Abcam) and anti-
VEGF (Santa Cruz Biotechnology) with pepsin antigen retrieval in paraffin sections.  Fragment 
blocking was performed overnight prior to addition of secondary HRP conjugated antibody.  
Anti-CD31 staining was used in mouse frozen sections to identify tumor blood vessels.  
TUNEL staining was performed using the DeadEnd Fluoremetric TUNEL system (Promega) 
with paraffin sections according to manufacturer’s instructions.   
 
Tumor Growth and Metastasis   
Female Athymic Balb/c nude mice were purchased from Tanomics and were housed in 
pathogen free conditions.  All studies were approved and supervised by The University of 
Texas MD Anderson Cancer Center, Institutional Animal Care and Use Committee (IACUC).  
For the tumor growth model, 1x106 cells were injected subcutaneously and tumor size was 
monitored twice a week for 27 days for Galectin-3 shRNA and 32 days for NFAT1 shRNA 
studies.  Ten mice per group and eight mice per group for Galectin-3 and NFAT1 in vivo 
studies respectively were used. Mice were then sacrificed and tumors were collected.  For 
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experimental lung metastasis, eight mice per group were sacrificed four weeks after 5x105 cells 
were injected intravenously as previously described [43]. 
 
Expression Microarray   
Total RNA was isolated from WM2664 NT and Galectin-3 shRNA melanoma cells.  RNA was 
converted into cRNA using the Illumina TotalPrep Amplificatin Kit (Ambion) and hybridized 
in triplicate to the HT-12 Version 3 Illumina chip.  Gene expression analysis was performed 
between the two samples. 
 
Statistical analysis   
Student’s t-test was performed for the analysis of in vitro assays.  The Mann-Whitney U test 












CHAPTER 3: Specific Aim 1 
 
Determine the In Vitro Migratory, Invasive, and Colony Formation 
Potential of Melanoma Cell Lines after Silencing Galectin-3 Expression 
with Lentiviral-Based shRNA 
 
Introduction 
 During the transition from the RGP to VGP, melanoma cells must acquire the ability to 
invade through the basement membrane and migrate into the dermis where they enter the 
vasculature and travel to distant sites of metastasis.  Galectin-3 could be a critical gene 
involved in this phenotype.  Previous studies have shown that the addition of carbohydrate 
recognition domain competitors such as lactose or MCP can reduce the motility and invasion of 
breast cancer cells [154, 155].  Interestingly, in the murine B16F10 melanoma cell line, MCP 
reduced their ability to grow in soft agar [156].  Our lab has previously silenced galectin-3 in 
C8161 cells and showed a significant reduction in their ability to invade through Matrigel 
coated membranes, and silencing galectin-3 reduced the activity of MMP-2 [114].  Other labs 
have over expressed galectin-3 in non-cancerous cells and have shown increased invasive and 
migratory properties [157].  Furthermore, imunohistochemical analysis of patients’ specimens 
identified galectin-3 to be highly overexpressed in primary and metastatic lesions as compared 
to benign nevi [103].  By evaluating previous evidence, we hypothesize that galectin-3 is a key 
player in the migratory and invasive phenotype of melanoma cells.  Therefore, we stably 
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silenced galectin-3 with a lentiviral construct to determine the in vitro effect on migration, 
























Expression Analysis of Galectin-3 in a Melanoma Cell Panel 
 We sought to determine the expression pattern of galectin-3 in our melanoma cell lines.  
We confirm that our more metastatic cell lines expressed higher levels of galectin-3 as 
compared to the less tumorigenic and metastatic melanoma cells.  As displayed in figure 4, our 
highly metastatic cell lines (TXM18, WM2664, WM902B, 451-Lu, and A375SM) express 
higher levels of galectin-3 as compared to the less tumorigenic and metastatic melanoma cells 
(SB2, DX3, and DM4).  Interestingly, C8161 melanoma cells, which are highly metastatic, 
invasive cells, express low levels of galectin-3.  Although lower than other metastatic cells, its 
expression was enough to deregulate IL-8, VE-cadherin, and fibronectin as our lab has 
previously shown.  Why galectin-3 is expressed less in c8161 is not completely understood.  
However, one brief study was performed.  Our cell panel can potentially be separated into three 
groups.  Those with NRAS, BRAFV600E/D, or other BRAF mutations.  If analyzed in this 
manner, a striking observation was found.  BRAFV600E/D mutant melanoma cells had higher 
levels of galectin-3.  However, this is only preliminary data.  A much larger scale analysis of 
galectin-3 corresponding to mutational status should be performed.  Therefore, this observation 
could be due to our panel lacking enough highly tumorigenic NRAs and non BRAFV600E mutant 





Figure 4.  Galectin-3 is Expressed at Higher Levels in Metastatic Human Melanoma Cell 
Lines 
 
Western blot analysis in melanoma cell lines was performed.  The less tumorigenic DX3, SB2, 
and DM4 melanoma cell lines express far less galectin-3 than the more tumorigenic and 
metastatic TXM-18, WM2664, A375SM, WM902B, and 451-Lu cells.  C8161 melanoma cells 
express less galectin-3; however, are still highly metastatic melanoma cells.  The NRAS and 













Silencing Galectin-3 in WM2664 and A375SM Metastatic Melanoma Cell Lines 
 To establish the role that galectin-3 melanoma cells have on melanoma progression, we 
chose to stably silence galectin-3 in two metastatic and invasive melanoma cell lines that have 
high levels of galectin-3 expression.   Of our cell panel, the cells that met these criteria were the 
WM2664 and A375SM melanoma cell lines.  The two melanoma cell lines were then stably 
transduced with non-targetable (NT) or galectin-3 shRNA packaged lentivirus.  The non-
targeting shRNA sequence has no known homology to any known human gene, and will be 
used as a control throughout the study.  The packaged vector utilizes the green fluorescent 
protein (GFP) based lentiviral system.  After transduction, the cells for both NT and galectin-3 
shRNA melanoma cells were sorted for the top thirty percent of GFP fluorescence (based of 
GFP expression) by Fluorescent Activated Cell Sorting (FACS).   
 After cell sorting, both WM2664 and A375SM melanoma cell lines transduced with NT 
or galectin-3 shRNA were grown. Western blot analysis was performed to determine the 
silencing efficiency of galectin-3 shRNA.  By utilizing densitometry to normalize galectin-3 
with actin, it was observed that both melanoma cell lines with galectin-3 shRNA have almost a 
complete knock down in galectin-3 expression as compared to the NT shRNA control (Figure 











Figure 5.  Stable Transduction of Galectin-3 shRNA is Efficient at Reducing Galectin-3 
Expression in both WM2664 and A375SM Melanoma Cell Lines 
 
Galectin-3 expression is almost completely lost in both melanoma cell lines with the stable 
lentiviral based transduction of galectin-3 shRNA.  Densitometry analysis for WM2664 cells 
confirms that approximately 90% of galectin-3 expression is lost.  For A375SM cells, galectin-









The In Vitro Migratory and Invasive Phenotype of Melanoma Cells After Silencing 
Galectin-3 
 To corroborate that galectin-3 reduces the migratory phenotype of melanoma cell lines, 
galectin-3 silenced WM2664 and A375SM melanoma cells were subjected to the modified 
Boyden chamber migration assay.  The cells were plated with serum free media in the top 
chamber and were incubated for 24 hours.  The bottom chamber contained MEM media with 
20% fetal bovine serum (FBS) to act as a chemoattractant.  The number of migrated cells 
through the Boyden chamber was then evaluated.  A significant reduction in the number of 
migrated melanoma cells was observed after silencing galectin-3 in both WM2664 and 
A375SM cell lines,*p < 0.01 (Figure 6).  A more than 5 fold reduction is observed in WM2664 
cells and more than 2 fold reduction with A375SM.  
 The lab has previously shown that silencing galectin-3 in C8161 cell lines reduce their 
invasive phenotype and reduced MMP-2 activity is observed [114].  To confirm that galectin-3 
plays a role in the invasive potential of both WM2664 and A375SM melanoma cells were 
plated in Matrigel invasion chambers with serum free media.  As with the migration assay, 20% 
FBS was used as a chemoattractant.  As seen in Figure 7, the invasive capacity of melanoma 
cells is significantly reduced after silencing galectin-3, p < 0.01, with more than a 10 fold 
reduction in WM2664 and 3 fold reduction in A375SM.  Therefore, our data supports the idea 















Figure 6.  The Migratory Phenotype of Melanoma Cells after Silencing Galectin-3 
The migratory phenotype of melanoma cells were analyzed by the Boyden chamber assay.  (A)  
The number of migrated cells was counted per field.  Silencing galectin-3 in both melanoma 
cell lines significantly reduced the number of migrated cells as compared to NT shRNA (*P < 
0.01).  (B)  Representative images are shown for the number of migrated cells for each cell line 






























Figure 7.  The Invasive Potential of Melanoma Cells after Silencing Galectin-3  
(A) The number of invaded cells through Matrigel is significantly reduced after silencing 
galectin-3 in both WM2664 and A375SM melanoma cells as compared to NT shRNA (*P < 
0.001).  (B) A representative image for each cell line with either NT or galectin-3 shRNA is 






















Soft Agar Colony Formation of Galectin-3 Silenced Melanoma Cells 
 The soft agar colony assay is a stringent method that has been widely used for the 
identification of anchorage independent growth and transformed cancers cells.  This method 
has also been used to isolate circulating melanoma cells from periphery blood samples of 
patients with metastatic disease [158].  Studies with murine fibrosarcoma cells identified that 
metastatic cell clones were able to grow colonies in 0.6% soft agar while non-metastatic clones 
were almost completely restricted in growth [159].  Selection of breast cancer cells in 0.9% 
agar created cell clones that were very similar in their molecular phenotype as those from in 
vivo brain metastasis [160].  This method could give us a good indication on whether galectin-3 
affects anchorage independent growth, a key indicator for the metastatic potential of melanoma 
cells.  To that end, WM2664 and A375SM NT and galectin-3 shRNA melanoma cells were 
mixed with 0.6% soft agar and plated.  After thirty days of incubation, the number of soft agar 
colonies was quantified.  As shown by Figure 8, silencing galectin-3 significantly reduced the 
number of colonies formed in soft agar from from 191 to 50 in WM2664 and from 131 to 40 in 













Figure 8.  Colony Formation of WM2664 and A375SM Melanoma Cells in 0.6% Agar 
After incubation in soft agar for 30 days, the mean number of colonies was counted in 
triplicate.  Silencing galectin-3 in WM2664 melanoma cells significantly reduced the number 
of soft agar colonies by more than threefold, while a greater than two fold reduction in the 












 Herein, we report that silencing galectin-3 in WM2664 and A375SM melanoma cells 
significantly reduces their migratory and invasive potential.  Galectin-3 has previously been 
shown to induce the migratory and invasive phenotype of cancer cells.  For example, silencing 
galectin-3 in B16F10 murine melanoma cells reduced MMP-1 expression and in vitro 
migration and invasion [107].  In sarcoma cells, galectin-3 increases the migratory phenotype 
in a carbohydrate dependent manner by activating PI3K and disrupting adhesion plaques [161].  
The exogenous expression of β1 integrin increases galectin-3 expression and the epithelial to 
mesenchymal transition (EMT) phenotype in GE11 cells [162].  We have previously shown 
that silencing galectin-3 in C8161 melanoma cells reduces their ability to invade through 
Matrigel coated membranes [114].  Therefore, our data corroborate previous studies.   
 The metastatic potential of melanoma cells relies heavily on the ability for cells to 
survive and proliferate in anchorage independent conditions.  The survival of melanoma cells is 
dependent on their ability to withstand the harsh microenvironment of the metastatic site.  The 
soft agar assay is a good prognostic tool for identifying the metastatic potential of melanoma 
cells as it too represents a harsh microenvironment in which the cells must survive and grow in 
an anchorage independent manner.  Guo et al have even suggested that the ability of cancer 
cells to grow in increasingly higher concentrations of soft agar, from 0.3% to 0.9% selects for 
more invasive breast cancer cells that are more likely to metastasize and grow in the brain of 
nude mice [160].  Metastatic fibrosarcoma clones are more likely to grow in 0.6% soft agar as 
compared to non-metastatic clones [159].  Silencing galectin-3 in both metastatic melanoma 
cell lines significantly reduced their ability to grow in 0.6% soft agar.  Therefore, we can 
predict that silencing galectin-3 reduces the metastatic potential of melanoma cells.      
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CHAPTER 4: Specific Aim 2 
 
Identification of Novel Downstream Target Genes of Galectin-3 that 
Contribute to the Metastatic Melanoma Phenotype 
 
Sub-Aim 2.1:  Galectin-3 as a potential regulator of Autotaxin Expression in 
Melanoma Cells  
 
Introduction 
Previous data has indicated that galectin-3 can have a profound effect on the 
transcriptional regulation of genes.  The overexpression of galectin-3 in breast epithelia cell 
lines changed the genomic signature that included genes such as cyclin D1.  The change in 
expression of these unique genes caused cell transformation of BT549 breast epithelial cells 
[148].  Our lab has previously identified IL-8, VE-cadherin, and fibronectin as downstream 
targets of galectin-3 [114].   
In aim 2, we sought out to identify novel downstream molecules regulated by galectin-3 
that contribute to melanoma growth and metastasis.  To further evaluate the effect galectin-3 
has on the gene expression profile of melanoma cells, a gene expression microarray was 
performed (Illumina).  Our microarray identified many potential targets including autotaxin 
(ENPP2).  The regulation of autotaxin by galectin-3 was previously unknown.  Therefore, we 
chose to elucidate this mechanism and identify how the interplay between these two molecules 
enhances melanoma progression. 
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Autotaxin was first identified as a pro migratory molecule in A2058 melanoma cells.  
However, the mechanism by which autotaxin enhanced their motility was unclear [163].  
Although secreted, autotaxin was not considered a ligand for any known receptors.  Only later 
was it realized that autotaxin contains a phosphodiesterase catalytic site that is required for the 
migratory phenotype [164].  Further evaluation matched the structure of autotaxin with a 
lysophospholipase D enzyme purified from fetal bovine serum which catalyzes 
lysophosphatidylcholine (LPC) to the bioactive lipid, lysophosphatidic acid (LPA) [165].  LPA 
then acts as ligand for two types of G-protein-coupled receptors.  This includes three from the 
endothelial differentiation gene (EDG) receptor family termed LPA1, LPA2, and LPA3.  Three 
other receptors that respond to LPA are structurally similar to the purinergic receptor family 
and are termed LPA4, LPA5, and LPA6 [166, 167].  Activation of LPA receptors enhances G-
protein signaling and downstream targets such as PI3K/AKT, PKC, cAMP, and Ca+ influx 
[167].  This results in enhanced chemotaxis, migration, invasion, angiogenesis, and 












Silencing Galectin-3 Changes the Gene Expression Profile of WM26644 Melanoma Cells 
 To identify novel downstream targets of galectin-3, a cRNA microarray was performed 
with the Illumina HT-12 Version 3 chip.  RNA from three separate 10cm dishes for both 
WMM2664 NT shRNA and galectin-3 shRNA cells were used to confirm reproducibility.  The 
gene expression profile was randomly grouped.  As expected, the three NT shRNA samples 
grouped with each other while the three galectin-3 shRNA samples generated another group 
with a similar gene expression profile (Figure 9).  Our initial data suggest that silencing 
galectin-3 does indeed deregulate multiple genes in melanoma cells.  We then analyzed our 
data to identify the genes with the greatest fold change in gene expression.  We focused our 
attention on genes down regulated after silencing galectin-3 as they could likely be tumor 
promoting genes.  The top identified genes were then sorted with ingenuity software based on 
their phenotypic function such as invasion, cell cycle, and tumor malignancy.  The top potential 
candidate genes are shown in Table 2.  Many pro-tumor genes such as endothelin receptor B, 
cathepsin K and B, cyclin dependent kinases, and l-plastin had reduced expression after 
silencing galectin-3 according to the gene microarray.  Of the several potential genes, we 
focused our attention on autotaxin.  Autotaxin was chosen due to previously published data that 
suggest autotaxin can enhance invasion, migration, and tumorigenicity.  These same 
phenotypes are observed with galectin-3.  Therefore, we hypothesize that galectin-3 might 








Figure 9. The Heat Map Comparing WM2664 NT shRNA with Galectin-3 shRNA 
Transduced Melanoma Cells 
 
Total mRNA was isolated from three separate 10cm dishes for both WM2664 NT shRNA and 
galectin-3 shRNA.  The cRNA from each sample was hybridized on an HT12 chip, Illumina.  
The three NT shRNA grouped together in a distinctly different gene expression profile from the 
























































Invasion Autotaxin (ENPP2) 2.33 
 Osteopontin (SPP1) 2.05 
Malignancy Galectin-3 (lgals3) 7.14 
 Stearoyl-CoA desaturase (SCD) 4.07 
 Osteopontin (SPP1) 2.05 
 Endothelin receptor B (EDNRB) 2.00 
Cell Cycle Cyclin A2 (CCNA2) 1.88 
 
 
Cyclin C (CCNC) 1.66 
CDC25B 1.90 
Other L-plastin (LCP1) 4.506 
 Endothelin receptor like b 2.08 
 Cathepsin B 1.59 
 Cathepsin k 1.93 
 MAPKKK1 1.74 
 HIF-2α (EPAS1) 1.57 
 
 
Table 2.  Top Potential Genes Down Regulated after Silencing Galectin-3 
The top potential candidate genes are shown.  These genes were down regulated after silencing 
galectin-3 in WM2664 melanoma cells as compared to the non-targeting (NT) control.  The 
candidate genes were further subgrouped by ingenuity pathway analysis into known 
phenotypes caused by each gene.  Note that our gene expression array confirmed that galectin-3 









Autotaxin Expression and Activity is Reduced in Melanoma Cells after Silencing 
Galectin-3 
 To corroborate our initial gene expression microarray, qRT-PCR and Western blot 
analysis was performed to measure autotaxin expression in WM2664 and A375SM melanoma 
cells transduced with NT or Galectin-3 shRNA.  Indeed, the mRNA expression of autotaxin 
was reduced by more than two fold after silencing galectin-3 in both melanoma cell lines 
(Figure 10A).  Interestingly, intracellular autotaxin protein expression by whole cell lysis was 
unidentifiable.  However, autotaxin is primarily secreted from cells were it performs its 
biological function.  Therefore, the supernatant of melanoma cells was collected from non-
targetable or galectin-3 shRNA melanoma cells after 48hr incubation in serum free media.  
After methanol precipitation and isolation of the protein within the supernatant, a western blot 
was performed to identify the amount of autotaxin.  As shown in Figure 10B, silencing 
galectin-3 drastically reduces the amount of autotaxin within the supernatant by more than 
tenfold.    The disparity between mRNA and protein expression is not fully understood.  One 
possibility is that silencing galectin-3 additionally reduces the translation rate or protein 
stability of autotaxin by unknown mechanisms.  Another is that our method of precipitation and 
isolation of the supernatant results in low yields of protein.  Five to ten µg of total lysate is 
loaded per well.  Our autotaxin antibody might not be able to read such low levels of autotaxin 
expression in our gal-3 shRNA cells and thus, the amount of protein between groups appears 
greater.  Nevertheless, these data confirm our initial microarray studies by which autotaxin 
expression is reduced after silencing galectin-3.    
 Although we identified that autotaxin protein levels are indeed reduced, we have yet to 
determine whether this has any relevance on tumor cell biology.  Our foremost objective was to 
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determine whether autotaxin from our melanoma cells is indeed enzymatically active within the 
supernatant.  To that end, we generated a protocol based on the autotaxin activity assay from 
Echelon.  In this assay, the compound FS-3 is used.  FS-3 is similar in structure as the 
endogenous lipid LPC.  However, FS-3 contains a quencher where choline is located on LPC, 
and a fluorescent labeled R group (Figure 11A).  If autotaxin is present in the system, it will 
cleave the quencher in the same manner it cleaves choline from LPC.  This results in a 
fluorescent signal that is quantified by a fluorescent plate reader.  To analyze FS-3 fluorescence 
in our study, 1x106  melanoma cells were grown over a 24 hour period in serum free conditions 
followed by concentrating the supernatant to a total volume of 200ul.  The media was then split 
into triplicate wells (50ul per well) with 50ul of 2x reaction buffer containing FS-3.  As shown 
in Figure 11B, the amount of fluorescence is increased over a period of six hours in both 
WM2664 and A375SM NT shRNA melanoma cells.  However, after silencing galectin-3, the 
rate of fluorescent activity is significantly reduced in both cell lines (Figure 11B).  Autotaxin is 
the primary lysophospholipase D enzyme that converts LPC to LPA, and FS-3, and LPC 
analog, is considered to have a high affinity for autotaxin.  Therefore, we conclude that the 
reduced rate of FS-3 activity is contributed by reduced levels of autotaxin.  This can be 
translated to the biological system.  Lower levels of autotaxin should result in lower levels of 
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Figure 10.  Autotaxin Expression after Silencing Galectin-3 
(A)  The mRNA expression of autotaxin was analyzed after silencing galectin-3.  A more than 
two fold reduction was observed in both WM2664 and A375SM melanoma cells.  The error bar 
represents the Rq-Max of triplicate reactions.  (B)  The supernatant is collected from NT 
shRNA and Gal-3 shRNA transduced WM2664 and A375SM melanoma cells, concentrated, 
methanol precipitated, and suspended in 6M urea lysis buffer.  By western blot analysis, we 
observe a reduction of autotaxin expression after silencing galectin-3 by approximately tenfold 


















Figure 11.  Autotaxin Activity After Silencing Galectin-3 
(A)  FS-3 is composed of both a quencher and fluorescent tag.  The quencher mimics the 
choline site on LPC while the fluorescent tag replaces the R group.  A fluorescent reading is 
achieved when cleavage of the quencher occurs by autotaxin.  Adapted from Ferguson CG et 
al, Organic Letters 2006.  (B)  Mean fluorescence is plotted for each sample every two minutes 
for six hours (360 min).  WM2664 and A375SM NT shRNA cell lines have a higher rate of 
fluorescent activity as compared to galectin-3 shRNA transduced cells.  Equal volumes of the 




















Autotaxin is Regulated by Galectin-3 at the Transcriptional Level  
 Our initial microarray and qRT-PCR studies confirm that galectin-3 regulates autotaxin 
expression at the mRNA level.  However, we have yet to elucidate whether this is 
transcriptional or post-transcriptional regulation.  To that end, we adopted the nuclear run-on 
method from Patron et al [153].  The intact nucleus is collected and incubated with ATP, GTP, 
CTP, and biotinylated UTP.  The final mRNA transcript is transcribed by RNA polymerase II 
with the incorporation of biotinylated UTP.  Pull down of the freshly transcribed mRNA by 
streptavidin beads, followed by qRT-PCR allowed us to identify real time transcription of 
autotaxin from A375SM NT shRNA and galectin-3 shRNA melanoma cells.  As observed by 
qRT-PCR, the amount of autotaxin mRNA that was actively transcribed in galectin-3 silenced 
A375SM melanoma cells was reduced by more than threefold (Figure 12A).  MicroRNA’s can 
have a profound effect on mRNA expression.  We have yet to rule out that galectin-3 could 
differentially regulate genes such as microRNAs that could post-transcriptionally regulate 
autotaxin.  To rule out any added post-transcriptional regulation of autotaxin by galectin-3, the 
rate of mRNA degradation was analyzed after the addition of actinomycin D, an inhibitor of 
mRNA synthesis.  After standardizing both samples to one at time zero, there was no 
significant change in the degradation rate of mRNA (Figure 12B).  Therefore, the reduced 
levels of autotaxin after silencing galectin-3 is through its transcriptional regulation and our 
data suggest that microRNAs are not involved.   
With the nuclear run-on assay we were able to determine that autotaxin is regulated at 
the transcriptional level.  However, it was still unclear how silencing galectin-3 results in 
transcriptional repression.  To that end, the first 988 base pairs of the promoter prior to the 
autotaxin mRNA start site (~1Kb) were cloned and inserted in front of the luciferase gene in 
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the PGL3 vector. After transfection of the PGL3 vectors in WM2664 and A375SM NT or 
galectin-3 shRNA melanoma cells, luciferase activity was analyzed.  Luciferase activity was 
significantly reduced in both melanoma cell lines after silencing galectin-3 (Figure 13).  The 
1Kb promoter in front of the luciferase gene is less active in galectin-3 shRNA transduced 
melanoma cells.  Our data now confirm that the transcriptional regulation of autotaxin occurs 
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Figure 12.  Silencing Galectin-3 Reduces mRNA Transcription as Observed by the 
Nuclear Run-On Assay 
 
A375SM melanoma cells tranduced with NT or Galectin-3 shRNA were used to 
confirm that silencing galectin-3 reudces the transcriptional activation of autottaxin.  (A) The 
nuclear run-on assay was used with biotin labeld UTP.  Pull down of biotinylated mRNA 
follwed by qRT-PCR shows a reduced amount of freshly transcribed autotaxin mRNA by 
aproximately 3 fold.  (B) The rate of mRNA degradation is shown in the presense of 
actinomycin D over 12 hours.  Time zero was standardized to one for both A375SM NT and 
galectin-3 shRNA samples.  The rate of degradation does not change after silencng galectin-3.  
A drop at 4 hours is noticed in NT shRNA cells, however, this appears to be an outlier in our 
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Figure 13.  Dual Luciferase Activity of the Autotaxin Promoter is Reduced After Silencing 
Galectin-3 
 
PGL-3 basic (no promoter) or the autotaxin 1Kb-PGL-3 vector were transfected into (A) 
WM2664 or (B) A375SM melanoma cells.  Silencing Galectin-3 resulted in a significant 
reduction of luciferase activity in WM2664 melanoma cells (p<0.05) and was almost 












Silencing Galectin-3 Reduces the Protein Expression of the Transcription Factor NFAT1, 
a Known Regulator of Autotaxin 
Galectin-3 is not considered to have a direct effect on transcriptional activation.  In our 
system, it is likely that galectin-3 affects a signaling pathway that leads to the increased 
activation of specific transcription factors that enhance autotaxin expression.  Therefore, we 
analyzed the first 1Kb of the autotaxin promoter to identify potential transcription factor 
binding sites.  Through online Genomatix promoter analysis, more than 300 candidate 
transcription factors binding sites were found.  Two of these binding sites were for the 
transcription factor Nuclear Factor of Activated T-Cells 1 (NFAT1).  Both locations were 
within 500bp of the autotaxin mRNA site (Figure 14A).  
 NFAT1 belongs to the NFAT family of proteins that include NFAT1, 2, 3, 4, and 5.  
The DNA binding domain is highly conserved within the NFAT1 family which can interact 
with Fos/Jun to initiate transcriptional activation [171].  NFAT1 was originally identified in T-
cells as an inducible transcription factor that bound to the antigen receptor response element 
(ARRE-2) of the interleukin-2 (IL-2) promoter [172].  NFAT1 was found to be a downstream 
transcription factor of the canonical calcium signaling pathway and is tightly regulated by the 
Ser/Thr phosphatase calcineurin.  Once Ca2+ is released within the cytoplasm from 
compartments such as the endoplasmic reticulum, Ca2+ and the protein calmodulin bind to the 
calcineurin regulatory domain.  This generates a conformation shift to activate phosphatase 
activity.  Calcineurin then binds to NFAT1 and dephosphorylates it’s nuclear localization 
sequence (NLS).  “Unmasking” the NLS of NFAT1 enhances its transport into the nucleus and 
increases transcriptional activity of target genes [171, 173].  NFAT1 activation by calcium 
influx can be blocked with calcineurin inhibitors such as cyclosporine A (CsA) and tacrolimus 
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(FK506) [174].  Inhibition of Ca2+ mobilization by removing the stimulus or using calcineurin 
inhibition results in re-phosphorylation of NFAT1 within 5-15 min [175, 176].  Interestingly, 
this phenomenon in NFAT proteins can be repeated many times with the addition and removal 
of inhibitors.  This suggests that constant regulation of NFAT by calcineurin and active kinases 
maintains the homeostatic balance in T-cells [175, 177].   
 NFAT1 expression has also been implicated in cancer.  In breast cancer patient 
specimens, high expression of NFAT1 was identified in primary tumors and lymph node 
metastasis as compared to normal adjacent tissue [178].  Another group identified that NFAT1 
enhances breast cancer cell invasion by up regulating the pro-inflammatory gene 
cyclooxygenase-2 (COX-2) [179].  The forced expression of integrin α6β4 in breast cancer 
cells has been shown to activate NFAT1.  This resulted in increased binding of NFAT1 to the 
autotaxin promoter as observed by the electrophoretic mobility shift assay and increased 
cellular motility of breast cancer cells[180].  Little is known about NFAT1 in melanoma.  
However, both NFAT2 and NFAT5 activity are increased in a BRAFV600E-dependent 
mechanism in melanoma [181], and interestingly, NFAT1 knockout mice have fewer metastatic 
lesions when injected with B16F10 murine melanoma cells [182].  Recently, it has been 
reported that silencing NFAT1 or adding CsA resulted in increased cleaved caspase-3 and the 
number of apoptotic cells [183].   
Previous evidence connecting NFAT1 with autotaxin expression and cancer progression 
caused us to generate the hypothesis that galectin-3 regulates autotaxin potentially by 
regulating NFAT1.  Our initial study was to first identify the protein expression status of 
NFAT1 in our melanoma cells before and after silencing galectin-3.  To our surprise, a 
significant reduction in NFAT1 protein expression is observed when galectin-3 is silenced in 
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both WM2664 and A375SM melanoma cells (Figure 14B).  Therefore, it is likely that galectin-





























Figure 14.  NFAT1 Protein Expression is Reduced After Silencing Galectin-3 in 
Melanoma Cells 
 
(A) Two NFAT1 binding sites are located on the autotaxin promoter, both of which located 
within 300 bp of the transcriptional start site.  (B) The protein expression of NFAT1 was 
analyzed.  A significant reduction in NFAT1 was observed after silencing galectin-3 in both 





NFAT1 Enhances the Promoter Activity and Expression of Autotaxin  
 We expect that reduced NFAT1 protein expression after silencing galectin-3 will result 
in less bound NFAT1 to the autotaxin promoter.  To that end, we next tested whether galectin-3 
silencing affects the binding of NFAT1 by utilizing the chromatin immunoprecipitation (ChIP) 
assay.  We used an anti-NFAT1 antibody to IP DNA-NFAT1 complexes in melanoma cells.  
End point PCR was performed surrounding both NFAT1 binding sites.  As shown in Figure 15, 
NFAT1 binds to the promoter of autotaxin in both WM2664 and A375SM melanoma cells.  
When galectin-3 is silenced, no NFAT1 was bound to the autotaxin promoter in both melanoma 
cell lines (Figure 15).     
Chromatin immunoprecipitation confirms that NFAT1 binds to the autotaxin promoter.  
NFAT1 binding is lost after silencing galectin-3.  However, it is unclear whether bound NFAT1 
on the promoter has an effect on transcriptional activation.  To further establish the role NFAT1 
has, the dual luciferase promoter assay was used with mutations in the autotaxin promoter at 
site 209, 290, or dual mutation.  Silencing galectin-3 results in an ~50% reduction of luciferase 
activity with the wild type promoter (Figure 16) corroborating our initial luciferase assay 
(Figure13).  When the mutated promoters are inserted into NT shRNA melanoma cells, the 
luciferase activity is also reduced to ~50% of the wild type promoter. The mutations have no 
effect on luciferase activity in galectin-3 silenced melanoma cells as compared to the wild type 
promoter (Figure 16).  Therefore, it is likely that our reduced promoter activity after silencing 
galectin-3 is a direct result of reduced NFAT1 protein expression and binding to the autotaxin 
promoter.  Interestingly, the dual mutation did not have an additive effect.  This result suggests 
that both sites are equally critical for transcription.    
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   Whether NFAT1 affects endogenous autotaxin expression has yet to be determined.  
Thus, we sought to test whether silencing NFAT1 reduces autotaxin expression in melanoma.  
To that end, NFAT1 was transiently silenced with NFAT1 siRNA in WM2664 and A375SM 
cell lines.    After 48 hours incubation in serum free media, total cell lysate was collected and 
the supernatant was concentrated, methanol precipitated, and suspended in 6M urea lysis 
buffer. As shown in Figure 17A, transient NFAT1 siRNA efficiently knocks down NFAT1 
expression in the total protein lysate, and this resulted in reduced autotaxin expression within 
the supernatant.  The overexpression of NFAT1 in SB-2 (low metastatic, NFAT1 negative) 
melanoma cells resulted in a significant increase of autotaxin expression within the supernatant 
(Figure 17B).  However, there are two bands present when probed for autotaxin.  The larger 
band consists of isoform 1.  It is likely that the lower molecular weight band is another isoform 
of autotaxin (isoform 2 or 3), or is a non-specific band.  Interestingly, this band is not seen in 
our more metastatic cell lines.  These data concluded that the transcription factor NFAT1 drives 
autotaxin expression in melanoma. 
A more efficient, stable knockdown of NFAT1 was achieved in A375SM with lentiviral 
shRNA targeting NFAT1 (Figure 18A).  Autotaxin expression within the supernatant was 
significantly reduced, corroborating our siRNA results (Figure 18A).  Since the conversion of 
LPC to LPA is the primary function of autotaxin, the autotaxin activity assay was performed 
with the compound FS-3 to determine whether reduced expression of NFAT1 results in less FS-
3 fluorescence in vitro.  Indeed, A375SM melanoma cells with stable NFAT1 silencing results 





Figure 15.  Chromatin Immunoprecipitation of NFAT1 on the Autotaxin Promoter is Lost 
after Silencing Galectin-3  
 
Endpoint PCR was performed surrounding both NFAT1 binding sites on the autotaxin 
promoter.  Chromatin immunoprecipitation of NFAT1 with anti-NFAT identifies a PCR 
product in NT shRNA transduced WM2664 and A375SM cells.  No PCR product is amplified 
in galectin-3 shRNA transduced melanoma cells.  Nonspecific IgG was used as a negative 








Figure 16.  Dual Luciferase Promoter Activity is Reduced in the Presence of NFAT1 
Binding Site Mutations 
 
Silencing galectin-3 in both WM2664 and A375SM significantly reduced the luciferase 
promoter activity of the wild type promoter by approximately 40% (white bar,) as compared to 
NT shRNA (black bar); **P < 0.01 and *P < 0.05 respectively.  Mutating either NFAT1 
binding site at location 209 or 290 resulted in reduced promoter activity to approximately 50% 
of the wild type promoter; **P < 0.01 and *P < 0.05.  Dual mutations were not significantly 
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Figure 17.  Silencing NFAT1 Decreases Autotaxin Expression in Melanoma Cells 
(A) The addition of NFAT1 siRNA effectively reduces NFAT1 expression in both WM2664 
and A375SM melanoma cell lines.  The resulted in approximately a 70% reduction of autotaxin 
expression within the supernatant in WM2664 and a 40% reduction of autotaxin in A375SM 
cells.  Coomassie blue staining of the membrane was used to confirm equal loading of the 
supernatant.  (B) Over expression of NFAT1 in low metastatic non NFAT1 expressing 
melanoma cells increases the expression of two bands around the same molecular weight as 
autotaxin by 9.7 fold.  The upper band likely isoform 1 and the lower band potentially being 













Figure 18.  Silencing NFAT1 in A375SM Melanoma Cells Reduces Autotaxin Expression 
and Activity 
(A) Stable knockdown of NFAT1 was achieved with lentiviral base NFAT1 shRNA as shown 
in whole cell lysate.  NFAT1 shRNA effectively reduces autotaxin expression isolated from the 
cell culture supernatant.  Coomassie blue staining of the membrane is shown for equal loading 
of the supernatant.  (B) The fluorescent readout of FS-3 was obtained every two minutes for 6 
hours (360 min).  A375SM melanoma cells transduced with NFAT1 shRNA cleaved FS-3 at a 
lower rate than NT shRNA transduced A375SM cells.  Silver staining of a gel with equal 
volumes of the supernatant that were used for the autotaxin activity assay were ran to confirm 








Rescue of Galectin-3 in Melanoma Cells Results with the Rescue of NFAT1 and 
Autotaxin.   
 Lentiviral based shRNA is a powerful tool for silencing the expression of target genes.  
However, this method can cause unwanted, nonspecific effects due to targeting the wrong 
genes or by causing an antiviral response to double stranded mRNA.  To rule out these effects, 
galectin-3 was rescued in both WM2664 and A375SM galectin-3 shRNA melanoma cells.  We 
were able to rescue galectin-3 in A375SM melanoma cells and partially rescue galectin-3 in 
WM2664.  This resulted in the re-expression of NFAT1 and autotaxin in both melanoma cell 
lines while the empty vector control had no effect (Figure 19).  Therefore, the deregulation of 
autotaxin and NFAT1 is not generated by off target effects of galectin-3 shRNA.  These 
















Figure 19.  The Rescue of Galectin-3 Rescues NFAT1 and Autotaxin Protein Expression 
The Rescue of Galectin-3 is shown for both WM2664 and A375SM melanoma Cells.  An 
increased expression of NFAT1 is observed after rescuing galectin-3 expression as compared to 
Galectin-3 shRNA cells transduced with an empty vector.  The amount of autotaxin expressed 
in the supernatant of melanoma cells is also increased in galectin-3 rescued cells.  The 
membrane with the supernatant is Coomassie blue stained and shown as an equal loading 







Galectin-3, NFAT1, and Autotaxin Expression are Positively Correlated in Melanoma 
Cells 
To our knowledge, the expression of NFAT1 has not been established in melanoma.  
Therefore, we analyzed the expression of NFAT1 by western blot in a panel of melanoma cell 
lines (Figure 20A).  The first observation is that the less tumorigenic and metastatic cell lines 
(SB-2, DM4, and DX3) express far less NFAT1 than the more metastatic cells (A375SM, 
WM2664).  Second, there is a positive correlation between galectin-3 expression and NFAT1, 
although, it is not a complete correlation.  This is evident in DX3 and 451-Lu melanoma cells.  
Although low levels of galectin-3 are observed, there is still a slight amount of NFAT1 
expression in DX-3 cells.  The opposite holds true for 451-Lu.  These cells express high levels 
of galectin-3, however, low levels of NFAT1 are observed.   
We then analyzed autotaxin mRNA expression in the same cell panel (Figure 20B).  
Melanoma cells that express high levels of galectin-3 and NFAT1 express autotaxin.  The cells 
that express low levels of galectin-3 and no NFAT1 do not express autotaxin. What is identified 
with the DX-3 and 451-Lu cells might shed some light between the correlation of NFAT1 and 
Galectin-3.  Although DX3 cells express a low amount of NFAT1, very low levels of autotaxin 
are observed.  In 451-Lu, there are higher levels of autotaxin mRNA.  These cell lines have 
comparable levels of NFAT1.  However, since higher levels of galectin-3 are present in 451-
















Figure 20.  The Expression of NFAT1 and Autotaxin in Melanoma Cell Lines 
(A) The protein expression of NFAT1 and Galectin-3 was analyzed by western blot in multiple 
melanoma cell lines.  Low expression of galectin-3 correlated with low levels of NFAT1 
protein expression.  High levels of galectin-3 correlated with high levels of NFAT1 protein 
expression.  The exception to this observation was 451-Lu, as it had high levels of galectin-3 
but low levels of NFAT1.  (B) The mRNA expression profile of autotaxin was compared 
between the same melanoma cell lines.  High levels of galectin-3 correlated with high levels of 
autotaxin.  Relative expression was standardized to 1 with the 451-Lu melanoma cells.  The 




















Galectin-3 Maintains the Expression of NFAT1 at the Post-Translational Level 
 The mechanism by which galectin-3 regulates NFAT1 remains elusive.  We first 
investigated the mRNA expression of NFAT1 after galectin-3 knockdown.  Interestingly, 
mRNA levels remained the same (Figure 21A).  This brought us back to what is observed with 
the cell panel.  The high galectin-3 expressing but with low expression of NFAT1 451-Lu cell 
line expresses autotaxin while the low galectin-3 expressing DX3 cells have 10 fold lower 
Autotaxin levels with the same amount of NFAT1.  This raises the possibility that galectin-3 
might affect NFAT1 activity as well as expression.  Perhaps in our melanoma cells, silencing 
galectin-3 results in reduced activity of NFAT1 which then leads to its degradation.  This is a 
bold hypothesis, however one experiment might suggest this to be correct.  NFAT activity can 
be analyzed by a simple western blot.  When NFAT1 is active, it becomes dephosphorylated.  
The dephosphorylated band is slightly lower in molecular weight.  This can even be seen in 
figure 20A, although the bands are so close they appear as one single band.  We therefore 
tested whether silencing galectin-3 increased NFAT1 protein stability.  To that end, we added 
the protease inhibitor to our cells 6 hours after transfection of a FLAG-tagged NFAT1 vector in 
WM2664 and A375SM NT and galectin-3 shRNA melanoma cells.  The cells were lysed 24 
hours later followed by immunoprecipitation with an anti-Flag antibody.  A western blot was 
performed targeting NFAT1.  What was observed was striking.  Transfection of FLAG-NFAT1 
at equal amounts with no protease inhibitor in both NT and galectin-3 shRNA had significant 
differences in protein expression when lysed 24 hours later (Figure 21B).  However, with the 
addition of Bortezomib, a proteasome inhibitor, NFAT1 levels in galectin-3 silenced cells were 
higher than without inhibition of the proteasome.  However, when protein expression is rescued 
with the proteasome inhibitor, the lower band representing active NFAT1 is still greatly 
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reduced in galectin-3 silenced cells.  This suggests that galectin-3 drives NFAT1 activity.  The 
loss of galectin-3 results in reduced transcriptionally active NFAT1.  Our data suggest that less 
active NFAT1 might lead to rapid degradation.  Further studies identifying how degradation of 

































Figure 21.  NFAT1 is Degraded at the Protein Level After Silencing Galectin-3 
(A) The mRNA expression of NFAT1 in WM2664 and A375SM melanoma cells after 
silencing galectin-3.  NFAT1 expression is similar in WM2664 melanoma cells and is 
minimally reduced after silencing galectin-3 in A375SM cells.  (B) Melanoma cells were 
transfected with FLAG-NFAT1 and immunoprecipitated with anti-FLAG.  Western blot 
against NFAT1 was performed.  Rapid loss of NFAT1 occurs in galectin-3 shRNA melanoma 
cells as compared to NT shRNA. The addition of the proteasome inhibitor Bortezomib at 20nM 
inhibits the loss of NFAT1 protein; however, it does not rescue its de-phosphorylation state 





















 Out of the galectin family of proteins, galectin-3 could potentially be the most diverse 
in its function.  It can affect biological functions through its carbohydrate binding properties 
that all galectins possess.  However, its unique chimeric protein structure that includes 
phosphorylation sites at the N-terminal end, a collagen like domain, and an NWGR “anti-
death” motif generate a dynamic molecule that performs non-carbohydrate binding functions as 
well.  It has been well established that galectin-3 can modulate the expression of genes 
involved in cancer progression, whether that be cyclin-D1, insulin like growth factor binding 
protein 5, IL-8, fibronectin, or VE-cadherin [114, 147, 148].  Phosphorylation of Ser6 on 
galectin-3 appears to be required for genetic transcription of cyclin-D1 and insulin like growth 
factor binding protein 5.  However, how Ser6 phosphorylation transcriptionally activates these 
genes remains unclear.  Reducing the total expression of galectin-3 has proven to reduce the 
expression of IL-8, fibronectin, and VE-cadherin.  In the present study, we sought to determine 
novel downstream targets of galectin-3 that have previously been unidentified.  By comparing 
the gene expression profile by cRNA microarray of WM2664 melanoma cells transduced with 
either NT shRNA or galectin-3 shRNA, we were able to confirm a specific gene expression 
profile of melanoma cells that is regulated by galectin-3.  More importantly, we identified 
multiple pro-tumorigenic genes that are down regulated after silencing galectin-3.  Therefore, 
galectin-3 might promote the metastatic melanoma phenotype by regulating these genes.  L-
plastin, osteopontin, autotaxin, hif-2α, and cathepsins B and K have all been implicated in the 
migratory, invasive or angiogenic phenotype [170, 184-187].  Endothelin receptor B and 
endothelin like receptor B were also identified in our microarray.  Endothelin receptor B 
stimulation by its ligand endothelin 3 (ET3) induces cell proliferation of A375 melanoma cells, 
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and endothelin receptor B antagonists can reduce cell viability in both A375 and WM35 cell 
lines [188, 189].  These are all ideal targets to further study.  However, our identified genes are 
only at the microarray level and must be further confirmed at the mRNA or protein level by 
qRT-PCR or western blot respectively.   
Of these genes, we singled out and validated autotaxin.  Our choice to selectively focus 
on the deregulation of autotaxin by galectin-3 is due to a variety of reasons.  First, autotaxin 
was identified as a motility factor for melanoma cells [163].  In our melanoma cells, we see a 
significant reduction in cell migration after silencing galectin-3.  Therefore, these two 
molecules could be intertwined in regards to the migratory phenotype.  Second, autotaxin is a 
lysophospholipase D enzyme secreted within the tumor microenvironment where it can 
produce the bioactive ligand LPA from LPC.  LPA can have significant effects on cancer cells 
as well as the surrounding tumor microenvironment.  For example, LPA can directly increase 
cancer cell invasion in vitro or can activate lymphatic and endothelial cells to induce tumor 
lymphangiogenesis and angiogenesis in vivo [190-192].  LPA production is the primary 
function of autotaxin.  Autotaxin itself does not directly bind to or activate any known 
pathways.  The phenotypic relevance of autotaxin is linked to LPA production.  Genetic 
instability of melanoma cells does not guarantee that an overexpressed gene is biologically 
functional.  Therefore, we tested the activity of autotaxin in melanoma cells.  High autotaxin 
activity was observed, and silencing galectin-3 in two melanoma cell lines significantly 
reduced the amount of autotaxin activity in vitro.  This confirms that autotaxin is functional in 
our melanoma cells, and galectin-3 could potentially increase the metastatic phenotype by 
regulating autotaxin.   
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However, the mechanism by which galectin-3 regulates autotaxin must be elucidated.  
The nuclear run-on assay was a critical experiment as it can confirm the endogenous 
transcription rate of autotaxin without the use of artificial promoters.  Artificial promoters can 
be misleading since upstream and downstream transcriptional activators that are required could 
be eliminated from the inserted promoter.  Our nuclear run-on assay suggested that autotaxin 
expression is reduced at the transcriptional level after silencing galectin-3.  The dual luciferase 
promoter assay in both WM2664 and A375SM melanoma cells confirmed this initial 
observation.  Due to previous publications that identify NFAT1 as a transcriptional activator 
that binds to the autotaxin promoter, we initially focused on this transcription factor.  To our 
surprise, silencing galectin-3 results in a dramatic reduction of NFAT1 protein expression.  
ChIP showed that bound NFAT1 to the autotaxin promoter is lost after silencing galectin-3.  
Mutations at both NFAT1 binding sites within the autotaxin luciferase promoter confirmed that 
both NFAT1 binding sites are equally critical for autotaxin transcription.  Mutating the NFAT1 
binding sites reduced promoter activity to that of galectin-3 shRNA cells. These data confirm 
that reduced levels of NFAT1 after silencing galectin-3 is the main contributing factor to 
decreased autotaxin expression.  
 We further investigated the effect of NFAT1 on autotaxin expression by transiently 
silencing NFAT1 in A375SM and WM2664.  This resulted in reduced autotaxin expression 
within the supernatant.  Overexpression of NFAT1 in SB-2 cells up-regulated autotaxin 
expression.  Stably silencing NFAT1 in A375SM melanoma cells not only resulted in the loss 
of autotaxin expression but also the amount of autotaxin activity within the supernatant as 
observed by the autotaxin activity assy.  The rescue of galectin-3 in WM2664 and A375SM 
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melanoma cells rescued both autotaxin and NFAT1.  Taken together, these data confirm that 
galectin-3 regulates autotaxin expression via NFAT1.   
What remains elusive in our study is the mechanism by which galectin-3 regulates 
NFAT1 protein expression.  We first reviewed our cRNA microarray; however, NFAT1 was 
not identified as a deregulated gene.  This made us lean towards the possibility that NFAT1 is 
regulated at the protein level.  Our results that show little change in mRNA expression of 
NFAT1 after silencing galectin-3 confirm our hypothesis.  Therefore, we sought out to identify 
how galectin-3 regulates the protein stability of NFAT1.  One of our first experiments was to 
immunoprecipitate NFAT1 and probe for ubiquitin, the posttranslational modification that 
leads to proteasome targeted degradation.  However, our western blots for ubiquitin showed no 
changes, although, this could have been due to a poorly exposed blot (data not shown).  We 
could not conclude that this was due to our technique or if this was biologically correct.  A 
different approach was then considered.  That was to add the proteasome inhibitor, 
immunoprecipitate NFAT1, and determine whether the proteasome inhibitor rescues the protein 
expression of NFAT1.  By this method, NFAT1 expression was rescued in galectin-3 silenced 
melanoma cells.  This result suggests that NFAT1 is sent for proteasome degradation at a 
higher rate when galectin-3 is silenced.  We also identified another phenomenon with this 
technique.  Even though we rescue NFAT1 protein expression, the dephosphorylation of 
NFAT1 is not rescued.  This is especially evident in A375SM melanoma cell line.  We 
therefore hypothesize that galectin-3 is required for activation of NFAT1, which requires 
dephosphorylation of the N-terminal regulatory domain.  A domain that is tightly regulated by 
calcineurin, casein kinase 1(CK1), and GSK3β.  What immediately stands out is that both CK1 
and GSK3β can phosphorylate galectin-3 as well.  It must be determined whether this is of 
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random coincidence or if these molecules are connected within a similar pathway.  Galectin-3 
binds to and is phosphorylated by GSK3β.  Although GSK3β is thought to inactivate NFAT1, 
Yoeli-Lerner et al. have shown that GSK3β is required to maintain NFAT1 protein stability and 
its transcriptional activity [193].  GSK3β might play a complex dual role in regulating NFAT1 
under certain conditions.  The fact that over 14 phosphorylation sites on NFAT1 on the nuclear 
localization sequence indicate that this could be so.  GSK3β could require galectin-3 as a 
scaffold type protein for its phosphorylation of NFAT1.  Immunoprecipitation of galectin-3 
followed by blotting for NFAT1 did not identify NFAT1 on the membrane, suggesting that 
galectin-3 and NFAT1 do not form a complex (data not shown).  However, our buffers and 
antibodies might not be used under the right conditions.  Protein stability of NFAT1 by GSK3β 
requires AKT mediated phosphorylation of GSK3 at Ser9 [193].  Interestingly, silencing 
galectin-3 has been shown to reduce the phosphorylation of both AKT and GSK3β.  This 
reduced the invasive phenotype of pancreatic cancer cells [108].  Therefore, it is possible that 
galectin-3 enhances the protein stability of NFAT1 through AKT/GSK3β.  Our microarray also 
identified GSK3 to be down regulated after silencing galectin-3.  However, very little change in 
GSK3β expression was observed at the protein level (data not shown).  Casein kinase 1 
phosphorylates both NFAT1 and galectin-3.  Galectin-3 is highly expressed in our melanoma 
cell lines that express NFAT1 as compared to those that have no to little NFAT1 expression.  
Galectin-3 might be the primary phosphorylating partner of casein kinase 1.  Silencing galectin-
3 then could allow for casein kinase to phosphorylate and inactive other molecules such as 
NFAT1.  However, this is a hypothetical conclusion with no evidence to suggest this occurs.  
Currently, no conclusive data has been collected to identify the mechanism by which galectin-3 
regulates NFAT1 protein expression.  
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The positive correlation between galectin-3, autotaxin, and NFAT1 is highly prominent 
in mutant BRAFV600E/D melanoma cell lines as compared NRAS mutants and other BRAF 
mutations (Figures 4 and 20A from the same western blot).  Although this is only correlative, it 
could be hypothesized that constitutively active BRAFV600E plays a role in driving the 
expression of galectin-3 and NFAT1 in melanoma.  Galectin-3 seems to regulate NFAT1 at the 
protein level; however, BRAFV600E/D activating mutation could be required for the transcription 
of NFAT1.  If this is the case, then galectin-3 mediated protein stability of NFAT1 would be 
highly relevant in BRAFV600E melanoma patients, but would have little significance in patients 
with WT BRAFV600E.  Observing the promoter activity of NFAT1 in the presence of inhibitors 
of BRAFV600E could determine whether these pathways are connected.  Further, a human tissue 
microarray comparing NFAT1 and galectin-3 expression in conjunction with the mutation 
status of BRAF will determine whether there is indeed a correlation between these three 
molecules in melanoma.  Comparing NFAT1 expression in A375 (a low metastatic cell line in 
mice) with the highly metastatic cell line A375SM will also determine whether NFAT 
expression is an early event or reliant on a more aggressive metastatic phenotype. Our cell 
panel contains only a small cohort of melanoma cell lines.  Future experiments performing the 
experiments discussed above will elucidate the contribution of BRAFV600E to the galectin-






Sub-Aim 2.2:  Autotaxin and NFAT1 Contribute to Melanoma Growth  
and Metastasis 
Introduction 
 Galectin-3 has been implicated in tumor cell migration, invasion, angiogenesis, tumor 
growth, and metastasis.  Herein, we identify a novel molecule, autotaxin, regulated by galectin-
3 via the transcription factor NFAT1.  We next sought out to determine whether galectin-3 
contributes to the metastatic melanoma phenotype by regulating autotaxin.  Autotaxin 
expression was first identified as a motility and invasive factor for melanoma cells [163]. The 
conversion of LPC to LPA by autotaxin is a powerful inducer of angiogenesis [194].  In this 
aim, we will elucidate whether galectin-3 enhances tumor growth, experimental lung 
metastasis, and angiogenesis in A375SM melanoma xenograft tumors due to its regulation of 
autotaxin.        
 The transcription factor NFAT1 is also identified as a novel downstream target of 
galectin-3.  Recently, NFAT1 has been found as a survival factor for melanoma cells under the 
pressure of MEK and BRAF inhibitors. However, no studies have been conducted in regards to 
its role in the melanoma invasive and the metastatic phenotype.  Therefore, we analyzed the 
contribution of NFAT1 to the invasive phenotype in vitro, and tumor growth and experimental 








The Over Expression of Autotaxin in Galectin-3 Silenced Cells Partially Rescues Tumor 
Growth and Metastasis In Vivo. 
 To validate the role autotaxin has in melanoma growth and metastasis, rescued 
autotaxin in our A375SM galectin-3 silenced melanoma cells.  We were able to generate a 
stable cell line with high levels of autotaxin expression and this translated to increased 
autotaxin activity (Figure 22 A and B).  These cells (A375SM galectin-3 shRNA / Autotaxin 
Rescue) were then injected subcutaneously in nude mice in parallel with A375SM NT shRNA 
and galectin-3 shRNA / empty vector.  Tumor volume was measured for 28 days and the rate of 
growth was compared between A375SM NT shRNA, galectin-3 shRNA / empty vector, and 
galectin-3 shRNA/autotaxin rescue.  Galectin-3 shRNA / empty vector   tumors were 
significantly smaller than NT shRNA tumors (Figure 23).  Immunohistochemistry confirmed 
that indeed autotaxin expression is increased in vivo in autotaxin overexpressing cells and 
galectin-3 remains silenced (Figure 23).  The rescue of autotaxin expression in galectin-3 
silenced tumors significantly increased tumor volume as compared galectin-3 shRNA / empty 
vector xenograft tumors (Figure 23).  However, the rescue of autotaxin in galectin-3 silenced 
melanoma cells did not completely restore tumor growth as compared to NT shRNA.  
Therefore, autotaxin expression is only one contributing factor.  Other factors by galectin-3 
most likely affect the remaining difference between tumor growth, such as its anti-apoptotic 
function and potential regulation of other pro-tumorigenic genes. 
Autotaxin and galectin-3 are both reported to enhance angiogenesis [194, 195].  To 
corroborate those claims, immunohistochemistry was performed on A375SM xenograft tumors 
with anti-CD31, a marker for blood vessels.  NT shRNA melanoma cells have a high number of 
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blood vessels as compared to galectin-3 shRNA / empty vector.  The overexpression of 
autotaxin in galectin-3 silenced melanoma cells rescued this phenotype (Figure 24).  This 
suggests that reduced angiogenesis after silencing galectin-3 is attributed to the loss of 
autotaxin.  VEGF was also stained within these tumors.  A slight reduction in VEGF staining 
was observed after silencing galectin-3; however, this was only a modest change (Figure 25).  
Circulating autotaxin is a strong inducer of angiogenesis as well [196].  Therefore we tested 
whether circulating autotaxin was reduced after silencing galectin-3.  Blood serum from tumor 
bearing mice was taken prior to sacrificing. The autotaxin assay was then used to identify the 
amount of circulating autotaxin within the blood.  Unfortunately, no detectable levels of 
autotaxin were observed (data not shown).  This could have been due to poor isolation of 
plasma, the majority of autotaxin secreted by the tumor cells stayed within the tumor 
microenvironment, or the protein was degraded quickly.  We also analyzed the number of dead 
melanoma cells within the tumors by the TUNEL assay.  The number of positively stained, 
dead tumor cells was significantly increased in galectin-3 silenced tumors.  The overexpression 
of autotaxin partially reduced the number of apoptotic cells (Figure 26).  This could be 
attributed by enhanced angiogenesis and access to nutrients and oxygen.  Another potential 
mechanism is that enhanced LPA synthesis in the tumor microenvironment could potentially 
activate LPA receptors on melanoma cells to increase cell survival.  The mRNA expression of 
six LPA receptors in A375SM melanoma cells were analyzed and compared with WM2664 and 
SB-2 melanoma cells.  High levels of LPAR1 were identified in both A375SM and WM2664 as 
compared to SB-2 (Figure 27).  Therefore, the autocrine loop of autotaxin secretion, LPA 
production, and LPA receptor signaling is likely to occur within the xenograft tumors. 
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A375SM melanoma cells transduced with either NT shRNA, galectin-3 shRNA/ EV, or 
galectin-3 shRNA/Autotaxin over expression were injected intravenously and the number of 
metastatic lung colonies were counted.  Galectin-3 shRNA / EV tumors produced significantly 
fewer metastatic lesions, 9, as compared to NT shRNA, 68.  The re-expression of autotaxin 
slightly rescued the number of metastatic colonies, 29 (Figure 28).  Therefore, the regulation of 
autotaxin by galectin-3 is an important contributor to the metastatic phenotype.  However, the 
re-expression of autotaxin does not completely rescue the number of experimental lung 
metastasis.  The carbohydrate binding and anti-apoptotic properties of galectin-3 or other 
metastasis associated genes regulated by galectin-3 likely contribute to the remaining 













      A.                          B. 
 
Figure 22.  The Over Expression of Autotaxin is Confirmed in A375SM Melanoma Cells 
(A)  Autotaxin is stably over expressed in A375SM melanoma cells with galectin-3 shRNA.  
The membrane is stained with coomassie blue for a loading control.  (B)  The cleavage of FS-3 
rapidly occurs after overexpressing autotaxin.  Therefore, we a capable of over expressing a 
functional autotaxin enzyme in A375SM galectin-3 shRNA transduced cells.  A silver stain of 






















Figure 23.  Re-Expression of Autotaxin in Galectin-3 Silenced Melanoma Cells Partially 
Rescues Tumor Growth 
 
(A)  A375SM melanoma cells with NT shRNA, galectin-3 shRNA / Empty vector, or galectin-
3 shRNA / Autotaxin were injected subcutaneously in nude mice.  Induced expression of 
autotaxin partially rescues tumor growth in galectin-3 silenced melanoma cells as compared to 
the empty vector control, *P < 0.01.  However, the rescue of autotaxin does not completely 
rescue tumor growth as compared to the NT shRNA transduced cells.  (B)  Galectin-3 remains 
silenced in the xenograft tumors.  Autotaxin re-expression is confirmed in galectin-3 shRNA / 


























Figure 24.  Microvascular Density is Increased in Galectin-3 shRNA Tumors that Have 
Autotaxin Over Expression 
 
A representative image of the number of CD31 positive endothelial cells is shown from 
xenograft A375SM tumors.  Silencing galectin-3 reduces the number of CD31 stained blood 
vessels within the tumor.  The re-expression of autotaxin in galectin-3 shRNA tumors rescues 








Figure 25.  VEGF Expression is Slightly Reduced After Silencing Galectin-3 
 
Immunohistochemistry for VEGF was performed.  Silencing galectin-3 slightly reduces the 
amount of staining for VEGF.  The rescue of autotaxin does not rescue VEGF expression 










Figure 26.  The Number of TUNEL Positive Cells in A375SM Xenograft Tumors 
Silencing galectin-3 significantly increases the number of apoptotic TUNEL positive cells 
within the subcutaneous tumor, *P < 0.01.  The rescue of autotaxin within these tumors 








Figure 27.  Relative mRNA Expression of LPA Receptors in Melanoma Cell Lines 
Six LPA receptors were analyzed by qRT-PCR and standardized to one with the low 
tumorigenic SB-2 cell line.  High levels of LPA1 are expressed in both WM2664 and A375SM 
as compared to SB-2 melanoma cells.  High levels of LPA1, 2, 4, 5, and 6 were seen in 
WM2664.  A375SM only express high levels of LPA1.  SB-2 melanoma expressed more LPA3 















Figure 28.  Reduced Lung Metastasis by Silencing Galectin-3 is Partially Rescued with the 
Re-Expression of Autotaxin 
 
A375SM melanoma cells transduced with NT shRNA, galectin-3 shRNA / Empty vector, or 
galectin-3 shRNA / autotaxin were injected intravenously in nude mice.  The number of 
metastatic lung colonies were then quantified.  (A) The number of experimental lung metastasis 
is reduced after silencing galectin-3 as compared to NT shRNA.  The re-expression of 
autotaxin partially rescues the metastatic phenotype of melanoma cells, *P < 0.01.  (B) The 
median number of metastatic colonies in the NT shRNA group was 68.  Silencing galectin-3 
reduced the median to 9 metastatic colonies, while re-expression of autotaxin increased the 











NFAT1 Expression is Required for the Malignant Melanoma Phenotype  
   Interestingly one group reported that B16F10 cells generate fewer lung metastasis in 
NFAT1 knockout mice, thus, NFAT1 could play a critical role in the tumor microenvironment 
[182].  However, how NFAT1 expression within melanoma cells contributes to the malignant 
phenotype has not yet been studied.  In breast cancer NFAT1 expression has been shown to 
enhance invasion through Matrigel [179].  To test whether the same phenotype is observed in 
melanoma, our SB-2 melanoma cells transduced with either an empty expression vector or 
NFAT1 from sub-aim 2.1 were subjected to the Matrigel invasion assay.  Interestingly, the 
overexpression of NFAT1 significantly increased the number of invaded SB-2 cells as 
compared to the empty vector control (Figure 29).  This invasive phenotype is contributed by 
many factors.  One of them is the induction of autotaxin expression (Figure 17) which has 
previously been shown as a pro-invasive molecule [197].  Other factors are most likely 
contributed to other downstream target genes that NFAT1 regulates.  These potential genes are 
now being investigated in our lab.  
 The in vitro invasive phenotype suggests that NFAT1 can contribute to a more 
aggressive and metastatic tumor.  However, the role of NFAT1 on melanoma growth and 
metastasis has not yet been established.  Therefore, we decided to inject our highly metastatic 
A375SM melanoma cells stably transduced with NT or NFAT1 shRNA into nude mice (Figure 
30).  Tumor volume was measured for 32 days after subcutaneous injections of A375SM NT or 
NFAT1shRNA melanoma cells.  Indeed, silencing NFAT1 significantly reduced tumor growth 
in vivo, *P <0.05 (Figure 30A).  To analyze the metastatic phenotype after silencing NFAT1, 
A375SM melanoma cells were injected intravenously.  A375SM melanoma cells transduced 
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with NFAT1 shRNA had a dramatic and significantly fewer lung metastasis than the NT 

































Figure 29.  NFAT1 Increases the in Vitro Invasive Phenotype 
SB-2 melanoma cells were stably transduced with an NFAT1 or empty vector (EV) expression 
lentivirus (see figure 17).  They were then subjected to the Matrigel invasion assay.  Expressing 
NFAT1 significantly increased the number of invaded cells through the Matrigel coated 




















A.                                                 B. 
 
 
Figure 30.  Silencing NFAT1 in A375SM Melanoma Cells Reduces Tumor Growth and 
Experimental Lung Metastasis in Nude Mice 
 
A375SM melanoma cells were (A) injected subcutaneously in nude mice and tumor growth 
was monitored for 32 days.  Tumor growth was significantly reduce after silencing NFAT1 at 
day 24, 28, and day 32 (*P  < 0.001).  (B) Six weeks after intravenous injection of A375SM 
cells, nude mice were sacrificed and the number of lung metastasis were counted.  Silencing 














Our lab has previously shown that silencing galectin-3 in C8161 melanoma cells could 
reduce tumor growth and metastasis.  In our study we corroborate those results with the 
A375SM melanoma cell line.  We also identify autotaxin as a downstream target of galectin-3.  
However, we have yet to confirm whether galectin-3 contributes to tumor growth and 
metastasis through its regulation of autotaxin.  To that end, we stably expressed autotaxin in 
galectin-3 silenced A375SM melanoma cells and injected these cells subcutaneously.  Tumor 
growth was compared with A375SM NT shRNA and galectin-3 shRNA / empty vector 
transduced melanoma cells.  Partial rescue of tumor growth was observed.  Interestingly, the 
microvascular density as shown by CD31 staining was completely rescued in galectin-3 
silenced / autotaxin re-expressed melanoma xenograft tumors.  Autotaxin is a powerful 
angiogenic factor.  In zebrafish, normal vascular development during embryogenesis requires 
the expression of autotaxin and LPA receptors [198].  Purified autotaxin mixed with Matrigel 
plugs generated new blood vessels to the same extent as vascular endothelial growth factor 
(VEGF).  Only a few blood vessels formed in Matrigel without VEGF or autotaxin [199].  
Interestingly, VEGF can stimulate autotaxin expression in endothelial cells [200].  Expression 
of autotaxin can then increase the migratory phenotype of HUVEC cells. This is highly reliant 
on the conversion of LPC to LPA.  The addition of LPC stimulates HUVEC motility; however, 
silencing autotaxin eliminates the number of migrated endothelial cells in the presence of LPC 
[200].  Furthermore, silencing autotaxin in HUVEC cells reduced the expression of the VEGF 
receptor VEGFR2 [200].  This implicates both VEGF and autotaxin in a positive feedback loop 
by which VEGF induces autotaxin expression, and conversion of LPC to LPA led to the 
activation of LPA receptors which would promote VEGFR2 expression [199, 200].  In a chick 
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embryo model however, LPA receptor antagonists did not reduce VEGF mediated angiogenesis 
while it significantly reduced LPA mediated angiogenesis [192].  Therefore, these two 
pathways are not completely reliant on each other to induce the angiogenic phenotype.   
Our data suggest that autotaxin/VEGF cross talk is not as prominent.   Only a slight 
reduction in VEGF expression is observed after silencing galectin-3, and the amount of VEGF 
is slightly rescued when autotaxin is overexpressed in our galectin-3 shRNA melanoma cells.  
VEGF might play a small role in inducing angiogenesis in A375SM xenograft tumors.  Most 
likely, galectin-3 contributes to angiogenesis in A375SM xenograft tumors by inducing 
autotaxin expression and LPA production.  Immunohistochemistry identified decreased 
expression of autotaxin in A375SM galectin-3 shRNA / empty vector tumors as compared to 
NT shRNA xenografts.  In cell culture, silencing galectin-3 resulted in reduced autotaxin 
activity within the supernatant as observed by our autotaxin activity assay.  Reduced levels of 
autotaxin are likely to contribute to our reduced autotaxin activity readout.  This is expected.  
Less autotaxin will result in less cleaved LPC to make LPA.  Although this is in vitro, we can 
expect this to occur in vivo as well.    Furthermore, LPA production within the tumor 
microenvironment can directly bind to melanoma cells and induce cell survival, proliferation, 
and chemotherapeutic resistance.  
Silencing galectin-3 significantly increased the number of TUNEL positive, apoptotic 
cells.  This could be due the reduced number of blood vessels and hence less oxygen and 
nutrients supplied within the tumor. Melanoma cells express LPA receptors and A375SM cells 
express high levels of LPA1.  Therefore, autotaxin can enhance cell growth and survival by 
directly affecting melanoma cells.  Autotaxin has been shown to increase chemotherapeutic 
resistance and cell survival of ovarian cancer cells [201].  Autotaxin expression can increase 
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the proliferation and motility of melanoma cells in vitro [165].  Autotaxin can induce the 
migratory phenotype through LPA activation of PI3kγ [202].  LPA can also enhance migration 
through p-21 activated kinase 1 (PAK1) phosphorylation and consequent focal adhesion kinase 
(FAK) activation [203].  Moreover, LPA receptor activation can lead to protein kinase C 
(PKC), NF-κB, phosphatidylinositol 3 kinase (PI3K), RAC, and RhoA activation.  All of which 
can contribute to cancer progression [200, 204-207].  The re-expression of autotaxin did not 
completely rescue cell survival.  Therefore, galectin-3 contributes to cell survival by potentially 
regulating other unidentified genes.  Also, it is well known that galectin-3 contains the NWGR 
antideath motif.  Galectin-3 can thus inhibit cell death by directly inhibiting cytochrome C 
release and cancer cell apoptosis [208].  This mechanism and other factors could be the 
remaining contributing factors by which galectin-3 increases cell survival. 
We have also identified the transcription factor NFAT1 to be regulated by galectin-3.  
NFAT1 has not been intensively studied in melanoma.  Only two publications, excluding our 
report, have discussed the role of NFAT1 in melanoma.  The first implicates NFAT1 as an 
important transcription factor in the stroma for the formation of a favorable metastatic niche.  
This was shown with NFAT1 knockout mice.  When B16F10 murine melanoma cells are 
injected in NFAT-/- mice fewer lung metastasis are formed as compared to wild type [182].  A 
similar phenotype was observed with galectin-3 knockout mice [99].  The other manuscript 
reports that silencing NFAT1 in combination with MEK or BRAF inhibitors sensitizes 
melanoma cells to apoptosis [183].  Yet, the role NFAT1 plays on the malignant melanoma 
phenotype has previously not been described.  Herein, we show that over expressing NFAT1 in 
low metastatic SB-2 melanoma cells increases their invasive phenotype.  In breast cancer, 
NFAT1 has already been established as a pro invasive transcription factor by inducing the 
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expression of COX-2 [179].  We did not determine whether COX-2 expression was affected in 
SB-2 melanoma cells after over expressing NFAT1.  However, autotaxin is significantly 
increased, and previous reports indicate that autotaxin enhances the invasive phenotype [209].  
Our data is the first report to show the importance of NFAT1 on the invasive phenotype of 
melanoma cells.  Other molecules besides autotaxin that are regulated by NFAT1 could 
contribute to the invasive phenotype as well.   
The tumorigenic potential of NFAT1 on melanoma cells has remained elusive.  
Therefore, we sought to elucidate the potential NFAT1 has on tumor growth and metastasis of 
melanoma cells.  Silencing NFAT1 significantly reduces tumor growth and experimental lung 
metastasis.  This could be due to the regulation of autotaxin by NFAT1.  Other genes regulated 
by NFAT1 could also contribute to tumor growth and metastasis.  Future studies need to be 
conducted to elucidate whether they contribute to the malignant melanoma phenotype. 













 In our study, we further establish the contribution by which galectin-3 promotes the 
metastatic melanoma phenotype.  We revealed the following novel findings which are 
summarized: 
1. Silencing galectin-3 by lentiviral shRNA in two metastatic melanoma cell lines 
significantly reduces their migratory and invasive potential in vitro.  Silencing galectin-
3 significantly reduces the ability of melanoma cells to survive and proliferate in an 
anchorage independent manner in soft agar.   
2. Galectin-3 positively regulates the expression of Autotaxin and NFAT1. 
3. Silencing galectin-3 reduces the transcriptional expression of autotaxin via down 
regulating the protein expression of the transcription factor NFAT1. 
4. Galectin-3 promotes Lysophospholipase D enzyme activity as observed by the FS-3 
autotaxin assay by regulating autotaxin expression. 
5. The rescue of galectin-3 in galectin-3 silenced cells restores the protein expression of 
both NFAT1 and autotaxin.  This confirms that our results are not an off-target effect of 
galectin-3 silencing. 
6. Silencing galectin-3 reduces the tumor growth and metastasis of A375SM melanoma 
cells.  The re-expression partially rescues the proliferative and metastatic properties, 
indicating that the regulation of autotaxin by galectin-3 contributes to the malignant 
melanoma phenotype.  Angiogenesis is almost completely rescued with the re-
expression of autotaxin; therefore, galectin-3 mediated angiogenesis is reliant on its 
regulation of autotaxin. 
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7. NFAT1 induces the invasive phenotype in vitro and silencing NFAT1 in melanoma 
cells significantly reduces tumor growth and metastasis. 
 
Taken together, our study identifies a previously unknown role by which galectin-3 
promotes melanoma growth and metastasis.  We have identified a novel pathway regulated 
by galectin-3.  Galectin-3 positively regulates the protein expression of the transcription 
factor NFAT1, which in turn, induces the transcription of autotaxin.  Autotaxin is then 
secreted within the supernatant where it performs its lysophospholipase D enzyme activity 
to convert LPC to LPA.  LPA within the tumor microenvironment acts as a ligand for LPA 
receptors located on both melanoma cells and stroma to induce tumor growth, invasion, 
angiogenesis, and ultimately metastasis.  Figure 31 depicts our model described in this 
study.   
The carbohydrate binding function of galectin-3 and its role in metastasis has previously 
been established.  These studies where the first to implicate galectin-3 with cancer and 
metastasis.  Over time, the intracellular properties of galectin-3 were discovered.  
Furthermore, these properties have just as significant of a role in tumor progression as do 
the carbohydrate binding properties of galectin-3.  For instance, the anti-apoptotic function 
of galectin-3 can act as a pro-survival factor under chemotherapeutic stress.  The regulation 
of genes such as cyclin D, IL-8, and VE-cadherin identify an intracellular signaling role by 
which galectin-3 contributes to cell proliferation, tumor growth, and vasculogenic mimicry.  
It is easy to understand how galectin-3 earns the chimeric name in both its protein structure 
and its multiple biological functions.  Our study adds another layer to the intracellular 
network and how galectin-3 mediates its signaling.  However, we have yet to fully 
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understand how galectin-3 regulates NFAT1 protein expression.  Whether galectin-3 acts a 
scaffold protein, dominant negative for casein kinase 1 phosphorylation, or other unknown 
mechanisms will need to be established.   
Therapies targeting galectin-3 and autotaxin have long been studied.  Throughout our 
study, we identify a novel molecule in melanoma, NFAT1, that promotes the malignant 
phenotype.  Targeting NFAT1 could be another potential therapeutic tool.  Therapy directed 
at NFAT1 is clinically feasible as shown with cyclosporine A to inhibit T-cell mediated 
organ transplant rejection [210].  However, in melanoma, immunotherapy and 
immunesurveillance promoted by T-cells are considered methods for melanoma treatment.  
Therefore, systemic therapy directed towards NFAT1 in melanoma could be 
counterintuitive by reducing T-cell activity.  Yet, not all T-cells have anti-tumor function.  
Regulatory T-cells (Treg) can reduce the immune response towards tumors, and it’s been 
shown that NFAT1 enhances Treg activity as well (Reviewed in [211, 212]).  The multiple 
roles of NFAT1 within the tumor microenvironment create a “double edged sword” in 
regards to its therapeutic potential.  Therefore, directing therapy towards galectin-3 instead 
of NFAT1 might be the most promising of all these treatments.  Modified citrus pectin 
directly targets galectin-3, reduces metastasis of B16F1 melanoma cells in 
immunocompetent mice with no toxicity, and potentially could inhibit downstream targets 
[213, 214].  Whether MCP can target intracellular galectin-3 or reduce the downstream 
functions, such as NFAT1/Autotaxin has not been studied.  The development of a small 
molecule inhibitor that targets the carbohydrate binding, anti-apoptotic, and cell signaling 
functions of galectin-3 could be a promising treatment modality for stage II or III 




Figure 31.  Proposed Mechanism by Which Galectin-3 Contributes to Melanoma 
progression 
 
Galectin-3 stabilizes NFAT1 protein expression.  NFAT1 binds to the promoter at both 209 and 
290 bp upstream of the transcription start site of autotaxin and induces its expression.  
Autotaxin is then secreted into the tumor microenvironment where it converts 
lysophosphatidylcholine into lysophosphatidic acid (LPA).  LPA binds to the LPA receptors 
located on melanoma cells to induce the metastatic melanoma phenotype.  In our melanoma 
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